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 ABSTRACT 
 
The Use of the Palladium-catalyzed Glycosylation for the Synthesis of 
C- and O-linked Glycosylated Natural Products  
 
Xiaomei Yu 
 
The carbohydrate portions of natural products play a crucial role in their 
pharmacological properties.  These properties can vary from improved water solubility, 
improved membrane transport properties, improved tissue targeting, as well as 
improved target binding. Herein we describe our efforts to use de novo synthesis to help 
elucidate the various roles carbohydrates play in biologically active glycosylated natural 
products. 
  The O’Doherty group has developed a method that uses asymmetric synthesis 
for the de novo synthesis of carbohydrates.  In contrast to traditional carbohydrate 
methods, this de novo approach builds the desired functionality and stereochemistry 
within each sugar. This methodology relies on a highly diastereoselective palladium(0)-
catalyzed glycosylation reaction to control the stereochemistry at the anomeric center 
and post-glycosylation transformation to introduce the corresponding functionality in 
the sugar moiety.  
       This de novo approach was first used in a highly enantio- and diastereoselective 
synthesis of Vineomycin C and PI-080.  The trisaccharide was made up of three rare 
sugars, an α-L-aculose, an α-L-rhodinose and a β-D-olivose. The key transformations 
 include: the palladium-catalyzed glycosylation, Myers’ reductive rearrangement, 
diastereoselective dihydroxylation, and regioselective Mitsunobu inversion. Material 
from this synthetic effort was used in several biological studies, such as 60-cell line 
cytotoxicity screens and apoptosis/necrosis mechanism of cell death studies.  
Significant apoptotic antitumor activity was found for this trisaccharide, which has 
implication for Vineomycin C and PI-080’s structure-activity relationship. To further 
elucidate the structural activity relationship for this trissacharide, we also prepared the 
enantiomeric D/D/L-trisaccharide, which is made up of α-D-aculose, α-D-rhodinose 
and β-L-olivose sugars. 
 To further study the structure activity relationship of these C-aryl glycoside 
natural products, an effort was undertaken to develop a selective method for the 
installation of a β-C-aryl glycoside bond to an intact di- and tri-sacchardes.  This began 
with a de novo synthesis of the disaccharide portion of two new C-aryl glycoside 
natural products, SCH-47554 and SCH-47555.  Unfortunately, despite the exhaustive 
screening of Lewis acid, no method was found for the formation of the desired β-C-aryl 
glycoside bond that did not occur with hydrolysis of the di- and tri-saccharide 
glycosidic bonds. 
 In the final chapter, an effort was described that was aimed at the synthesis of 
hydroxyl-substituted analogues of two biologically important natural products for 
further glycosylation.  The two natural products that were chosen for these studies were 
the poly-aromatic alkaloids ellipticine and camptothecin. This effort was aimed at trying 
to improve the water solubility/membrane transport properties of these anticancer 
 natural products.  While the efforts to prepare the required hydroxy-substituted aza-
ellipticin failed, a glycosylated camptothecin was prepared.  Unfortunately, the acid 
sestivity of the glycosylated camptothecin limits its use in biological studies. 
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Chapter I.  De Novo Asymmetric Syntheses of the Carbohydrate Portion of 
PI080 and Vineomycin C and its Enantiomer *,1 
 Two of the more structurally interesting classes of the anthracycline antibiotic are the 
angucycline and the vineomycins.2  Both families of antibiotics have been of particular interest to 
both the synthetic and biological communities due to their unique structures and potent antitumor 
and antibacterial activities.3  The structural diversity of these classes of natural products are 
typified by two different types of glycosylated aglycon ring systems. 4  Examples of the 
angucycline aglycones are the natural products WP-3688-2 and SS-22BY,5 as well as the 
urdamycinone aglycon (Figure 1). Of the angucycline aglycons, SS-22BY can be viewed as a 
dehydrated version of WP-3688-2 and both are oxidized forms of the urdamycinone aglycon. 
While it is also not an isolated natural product, the vineomycin aglycon is represented by the 
synthetic Vineomycinone B2 methyl ester aglycon.6 Both types of natural products share the 
anthraquinone ring system, with the angucycline ring systems having a D-ring annulated. 
Figure 1:  The angucycline/vineomycin aglycones 
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* Reproduced with permission from Org. Lett. 2008, 10, 4529-4532. Copyright 2008, American Chemical Society. 
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The two types of angucycline/vineomycin aglycone ring systems can be related by a D-
ring hydrolysis/methanolysis. This is exemplified by the conversion of WP-3688-2 to give the 
Vineomycin B2 methyl ester aglycon, which is outlined in Scheme 1. Similarly, the three types of 
angucycline type of aglycons are related by an oxidative dihydroxylation of the Urdamycinone 
aglycon to form the WP-3688-2 ring system and a dehydration of WP-3688-2 to form the SS-
22BY ring system. 
Scheme 1:  Hydrolytic conversion of angucycline to the vineomycin ring systems 
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 Most of the members of these two classes of natural products are glycosylated at the 
position ortho to the A-ring phenol (C-6 for vinomycins and C-9 angucyclines). Examples of 
these monosaccaride C-glycosides are antibiotics Aquayamycin, 7  Urdamycinone B 8  and 
Vineomycinine B2 (Figure 2).9 In addition to having antibiotic properties, Aquayamycin is 
known to inhibit tyrosine hydroxylase and Vineomycin B2 has been shown to have antitumor 
activity. All three of these natural products have succumbed to total synthesis.  
Figure 2:  The angucycline/vineomycin monosaccharides 
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 Outlined in Figure 3 is a list of the structures of the known vineomycin type antibiotics. It 
is interesting to note that Vineomycin A1 has the Urdamycinone ring system, which is consistant 
with the biosynthetic pathway that relates the two ring systmes (Scheme 1). This exception to the 
above classification probably resulted from the fact that the structures were named before the 
structures were elucidated. Hence the names that were chosen were based on the microbial 
species from which the natural products were isolated. With the exception of Vineomycin A1, the 
various vineomycins vary in degrees of glycosylation, with mono-, di-, and tri-saccharides at the 
C-6 position via a β-C-glycoside attachment and α-linked O-glycosides on the side chain. 
Figure 3:  The vineomycins 
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 Like the vineomycins, the angucyclines consist of members with varying degrees of 
glycosylation.  With mono-, di-, and trisaccharides at both the C-9 position (via a β-C-glycoside) 
and at the tertiary alcohol (via an α-O-glycoside). 
Figure 4:  Other glycosylated angucycline antibiotics 
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 Of all these structural diverse C-glycoside natural products, the O’Doherty group became 
interested in  PI-080 (1)10 and Vineomycin C (2).11  Both PI-08012 and Vineomycin C share a β-
C-glycoside link α-L-aculose, α-L-rhodinose (4), and β-D-olivose trisaccharide subunit, whereas 
PI-080 has an additional α-L-aculose-bis-α-L-rhodinose trisaccharide (3). In addition to 
representing a range of structures, the angucycline family of antibiotics possesses a range of 
biological activities.  The antibiotic Vineomycin C displays potent antitumor activity,13 whereas 
PI-080 strongly inhibits blood coagulation. 
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Figure 5:  Structures of PI-080 and vineomycin C  
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 While the antitumor activity of the angucyclines has been attributed to the anthraquinone 
portion of natural products,13 the anticoagulant activity of PI-080 appears to be associated with 
one of the trisaccharide portions of the molecule (i.e., the trisaccharide 3). As part of a larger 
effort to use the de novo synthesis of carbohydrates for medicinal chemistry, the O’Doherty 
group became interested in elucidating the structural origins of the anticancer activity of 
Vineomycin C.  In particular, we were interested in determining whether any of the antitumor 
activity associated with Vineomycin C could be attributed to the trisaccharide subunit 4 (R = 
OPMB).  
While there is no report of the total synthesis of PI-080 and Vineomycin B2,14 the 
synthesis of the trisaccharide portion 3 has been completed by Sulikowski.15  While the 
trisaccharide 3 could be obtained from natural sources, access to the trisaccharide subunit 4 (R = 
OPMB) required synthesis. Recently, the O’Doherty group had some success using a Pd-
catalyzed glycosylation and post-glycosylation reactions for the synthesis of several naturally 
occurring rare sugar structural motifs.16  In this chapter, my efforts towards the de novo synthesis 
of trisaccharide subunit 4 from commercially available acylfuran will be described, along with its 
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antiproliferative activity toward 60 tumor cells lines and apoptosis vs necrosis studies cell death 
mechanism studies. 
Scheme 2.  Structures of PI-080 and vineomycin C and their trisaccharide motifs 3 and 4 
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O
O
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O
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 Retrosynthetically, it was envisioned that the α-L-aculose and α-L-rhodinose subunits of 
trisaccharide 4 would come from two α-L-pyranones 5.  Similarly, it was conceived the β-D-
olivose ring of 4 would come from β-D-pyranone 6 (Scheme 3).  Previously, it was shown in the 
O’Doherty group that the two pyranones could be prepared from the corresponding enantiomeric 
furyl alcohols, which in turn could be prepared by a Noyori reduction of 2-acylfuran 8 (Scheme 
3).18,19 The 2-acylfuran is a rather inexpensive commodity chemical used in the food industry 
(from the Sigma-Aldrich at $0.07/g for a 10 Kg scale). 
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Scheme 3:  Retrosynthetic analysis of the vineomycin C trisaccharide 
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 Previously, we have shown that the required Pd-glycosyl donors α-L-pyranones 5 and β-
D-pyranones 6, as well as their enantiomers, could be prepared from 2-acylfuran 8 (Scheme 4). 
The stereodivergent route employed an enantioselective Noyori reduction (8 to 7/ent-7),17,18 an 
Achmatowicz oxidation and a diastereoselective t-butyl carbonate formation (Scheme 4).16,19  
The β-pyranone 6 could be isolated in 50% yield when the Boc-protection step was performed at 
elevated temperature ((Boc)2O/NaOAc in benzene at 80 °C).  Alternatively, α-pyranone 5 could 
be selectively prepared in 62% (α:β = 3:1) yield at low temperature ((Boc)2O/DMAP in CH2Cl2 
at –78 °C).  
Scheme 4:  De novo approach to D/L-, α/β-Boc-pyranones 5 and 6 
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 With a practical route to the desired pyranone glycosyl donors, we next turned our 
attention toward the preparation of 2-deoxy-β-L-olivose ring of the trisaccharide 4.  Previously, 
we reported an approach to 2-deoxy-β-glycoside associated with allo- and gluco-
stereochemistry.16,20 Key to the successful implementation of this strategy is the selective 
Mitsunobu-like inversion of the allo-stereochemistry of the digitoxose sugar 12 into olivose 
sugar 13 (Scheme 5).  
Scheme 5:  Synthesis of a protected β-D-olivose 13 
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O
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12
OPMBO
Me
HO
O
13
PNBz
6 9
Pd(0)/2PPh3 = Pd2(dba)3•CHCl3/4PPh3  
 
 In practice, we began with the palladium-catalyzed glycosylation (5 mol% 
Pd2(dba)3•CHCl3/10% PPh3)† of PMBOH with the β-D-pyranone 6 to form the β-benzyloxy 
pyranone 9 in 95% yield as a single diastereomer (Scheme 4).  Ketone reduction of pyranone 9 
with NaBH4/CeCl3 gave a mixture of allylic alcohols 10a/b in 99% yield (dr ~ 1.5 to 1).  
Fortunately, both diastereomers 10a/b could be used in the next reaction.  Applying the Myers’ 
reductive rearrangement conditions (NBSH, PPh3/DEAD, NMM, –30 ºC to rt)21 to the mixture of 
                                                
† To save space in the schemes these typical palladium glycosylation conditions (5 mol% Pd2(dba)3•CHCl3/10% 
PPh3) will be refered to as (5 mol% Pd(0)/2PPh3) to indicate the percentage of catalyst used in a 1:2 Pd/Ligand ratio. 
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allylic alcohols 10a/b cleanly provided olefin 11 in 95% yield.  Finally, exposing olefin 11 to the 
Upjohn conditions (OsO4/NMO)22 gave exclusively the diol 12 with allo-stereochemistry in 85% 
yield. We then turned to our selective diol inversion, subjecting 12 to the typical Mitsunobu 
conditions (p-NO2PhCO2H/PPh3/DIAD) cleanly converted it into the protected β-D-olivose 13 in 
70% yield.  A nice feature of this approach is that the nitrobenzoate group also serves as a 
temporary protecting group. 
Scheme 6:  Synthesis of a β-D-olivose/α-L-rhodinose disaccharide 17 
O CH3BocO
O
5% Pd(0)/PPh3
NaBH4, CeCl3
p-NO2PhCO2H
DIAD, PPh3
5(!-L)OPMB
O
Me
HO
O
13
PNBz
OPMBO
H3C
O
O
O
O
PNBzH3C
1498%
97%
OPMBO
H3C
O
O
HO
O
PNBz
H3C
15
80%
OPMBO
H3C
O
O
PNBzO
O
PNBzH3C
74%
16
LiOH OPMB
O
H3C
O
O
OH
O
HH3C
17  
 
 With a viable route to the protected β-D-olivo-sugar 13 in hand, our efforts turned to the 
installation of the α-L-rhodinose portion (Scheme 5). The olivo-sugar 13 and α-L-pyranone 5 
were coupled using our typical palladium-catalyzed glycosylation conditions (5 mol% 
Pd2(dba)3•CHCl3/10% PPh3, 98% yield) to form 14 with complete stereocontrol at the anomeric 
center. Luche reduction of the keto-group in pyranone 14 stereoselectively provided allylic 
alcohol 15 (97%).  At this stage, a Mitsunobu reaction (PPh3/DIAD/p-NO2PhCO2H, 74%) was 
used to afford bis-nitrobenzoate 16 with inverted stereochemistry at C-4.  Unfortunately, all 
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efforts to differentiate the two p-nitrobenzoate groups in 16 were unsuccessful.  As a result, we 
opted for hydrolyses of both benzoates with excess LiOH which afford diol 17 (80%) and then 
turned to the selective introduction of the α-L-aculose at C-4. 
Scheme 7:  Synthesis of the vineomycin C/PI-080 trisaccharide 19 
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 Our investigations of the selective introduction of the α-L-aculose at C-4 were performed 
on both diol 17 and diol 18 (Scheme 7), which could easily be prepared by hydrogenation with 
excess diimide (NBSH/Et3N, 80%). The Pd-catalyzed glycosylation (5 mol% 
Pd2(dba)3•CHCl3/10% PPh3) of alcohol 18 with α-L-pyranone 5 proved to be the better selective 
method.  This was most conveniently performed at low conversion using a slight excess of α-L-
pyranone 5 under dilute condition to provide 35% yield of the desired trisaccharide 19, along 
with 61% recovered starting material 18 (89% yield, based on recovered starting material). To 
confirm the regioselectivity of glycosylation, 19 was acylated with Ac2O/DMAP to form 20 
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(82%). Analysis of the one and two-dimensional NMR data of acetate 20 indicated that the 
glycosylation of 18 occurred selectively at the C-4 position of the α-L-rhodinose sugar. Overall, 
the trisaccharide 19 was prepared from the achiral 2-acylfuran 8 in 14 steps and 17% overall 
yield. 
Figure 6:  Proof of the regioselective glycosylation by NMR structural assignment of 20  
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With significant quantities of trisaccharide 19 in hand, we decided to screen it against 
two types of cancer cell lines from nine different tissue types (Table 1).  While we were 
motivated to test 19 primarily as a control experiement for future studies, we were delighted to 
find it had wide-ranging cytotoxicity, displaying significant growth inhibition (GI50 from 0.1 to 
11 µΜ) and cytotoxicity (LC50 from 5.1 to 100 µΜ) against these various cell lines. Indeed, at 50 
µΜ, the trisaccharide 19 showed greater cytotoxicity against NCI-H460 Non-Small Cell Lung 
cancer cells than Cisplatin at 300 µΜ (Figure 7). Interestingly, this level of cytotoxicity is in the 
range of that found for other glycosylated angucycline antibiotics.23  Outlined in Tables 2-10 are 
the results from the screening against the panel of the NCI’s 60 cancer cell lines for the same 
tissue types.  While good to moderate GI50 (1 to 20 µΜ) values were found across the board, 
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significant variation was found for the LC50 values (5 to >100 nM). 
Table 1:  Comparitive cytotoxicity evaluation of trisaccharide 19 across the cell lines 
 
19 (µΜ)  
cell type 
panel/cell line 
GI 50 TGI LC50 
RPMI-8226 0.12 2.80 > 100 Leukemia 
 SR 0.60 19.0 > 100 
NCI-H23 1.98 4.59 12.0 Non-Small Cell 
Lung NCI-H460 11.0 23.7 51.0 
COLO-205 1.66 3.02 5.50 Colon 
 SW-620 1.35 2.64 5.13 
SF-268 3.09 9.54 31.5 CNS 
 U251 1.82 4.10 9.26 
LOX IMVI 1.53 2.87 5.40 Melanoma 
 SK-MEL-28 1.82 3.22 5.71 
IGROV1 1.62 3.32 6.81 Ovarian 
 OVCAR-3 1.60 2.95 5.43 
TK-10 2.32 6.46 23.1 Renal 
 UO-31 1.49 2.81 5.30 
PC-3 1.74 3.99 9.16 Prostate 
 DU-145 1.81 3.20 5.66 
MCF7 1.63 3.38 7.04 Breast 
 T-47D 1.42 2.77 54.1 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
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Of all nine tissue types from the NCI panel of 60 cell lines, the trisaccharide 19 showed 
the worst potency against the leukemia cell line types.  While this poor activity was not so 
obvious from the GI50 growth inhibitory concentrations (ranging from 0.12 µΜ to 7.6 µΜ), the 
trend was most clear in the values of LC50 (> 100 µΜ).  The complete leukemia cell line data for 
trisaccharide 19 is outlined in Table 2.  
 
Table 2:  Leukemia cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Leukemia 
cell type 
panel/cell line 
GI 50 TGI LC50 
CCRF-CEM 0.30 > 100 > 100 
 
HL-60(TB) 0.65 > 100 > 100 
K-562 7.6 > 100 > 100 
 
MOLT-4 4.8 > 100 > 100 
RPMI-8226 0.12 2.80 > 100 
 
SR 0.60 19.0 > 100 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
The trisaccharide 19 showed much better potency against the Non-Small Cell Lung 
cancer cell line than the leukemia cell line.  The best activities came against the NCI-H23 (GI50 = 
1.98 µΜ and LC50 = 12.0 µΜ) and NCI-H522 (GI50 = 1.10 µΜ and LC50 = 5.41 µΜ) cell lines 
and the poorest activity came against the A459/ATCC (GI50 = 16.9 µΜ and LC50 = 60.8 µΜ) and 
HOP-62 (GI50 = 20.6 µΜ and LC50 = 61.7 µΜ) cell lines. The complete Non-Small Cell Lung 
(NSCL) cell line data for trisaccharide 19 is outlined in Table 3. 
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Table 3:  NSCL cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Non-Small Cell 
Lung 
cell type 
panel/cell line 
GI 50 TGI LC50 
A459/ATCC 
16.9 32.0 60.8 
 
HOP-62 
20.6 35.6 61.7 
HOP-92 
1.58 4.44 19.1 
 
NCI-H226 
13.7 26.6 51.6 
NCI-H23 
1.98 4.59 12.0 
 
NCI-H322M 
16.2 30.1 56.0 
 
NCI-H460 
11.0 23.7 51.0 
 
NCI-H522 
1.10 2.44 5.41 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
The trisaccharide 19 showed excellent potency across the board against the colon  cancer 
cell lines, with only the HC-2998 cell line showing LC50 values above 10 µΜ.  All the other cell 
lines had GI50 values between 1-2 µΜ concentrations and LC50 values between 5-7 µΜ 
concentrations.  The complete colon cancer cell line data for trisaccharide 19 is outlined in Table 
4. 
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Table 4:  Colon Cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Colon Cancer 
cell type 
panel/cell line 
GI 50 TGI LC50 
COLO-205 
1.66 3.02 5.50 
 
HC-2998 
3.56 11.8 34.4 
HCT-116 
1.18 2.53 5.46 
 
HCT-15 
1.50 3.04 6.15 
HT29 
1.53 2.86 5.46 
 
KM12 
1.67 3.30 6.55 
 
SW-620 
1.35 2.64 5.13 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
The trisaccharide 19 showed lesser potency against the panel of central nerous system 
cancer cell lines than the colon cell lines.  The best inhibitory activities came against the U251 
(GI50 = 1.82 µΜ and LC50 = 9.26 µΜ) and the poorest activity came against the SF295 (GI50 = 
13.7 µΜ and LC50 = 54.7 µΜ) cell lines. The complete central nervous system (CNS) cell line 
data for trisaccharide 19 is outlined in Table 5. 
 
16 
 
Table 5:  CNS Cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) CNS 
cell type 
panel/cell line 
GI 50 TGI LC50 
SF-268 
3.09 9.54 31.5 
 
SF295 
13.7 27.4 54.7 
SF-539 
3.33 13.7 37.1 
 
SNB-19 
12.2 24.6 49.6 
SNB-75 
1.11 12.2 34.9 
 
U251 
1.82 4.10 9.26 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
The trisaccharide 19 showed lesser potency against the panel of Melanoma cancer cell 
lines than the CNS cell lines.  The best inhibitory activities came against the LOXIMVI (GI50 = 
1.53 µΜ and LC50 = 5.40 µΜ) and SK-MEL-28 (GI50 = 1.82 µΜ and LC50 = 5.71 µΜ), with the 
poorest activity came against the UACC-257 (GI50 = 13.9 µΜ and LC50 = 53.8 µΜ) cell lines. 
The complete melanoma cancer cell line data for trisaccharide 19 is outlined in Table 6. 
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Table 6:  Melanoma Cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Melanoma 
cell type 
panel/cell line 
GI 50 TGI LC50 
LOX IMVI 
1.53 2.87 5.40 
 
MALME-3M 
2.0 5.23 20.9 
M14 
2.74 10.9 33.0 
 
SK-MEL-2 
2.58 6.97 24.5 
SK-MEL-28 
1.82 3.22 5.71 
 
SK-MEL-5 
8.19 20.6 45.4 
 
UACC-257 
13.9 27.3 53.8 
 
UACC-62 
3.89 14.4 38.0 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
The trisaccharide 19 showed the best across the board potency against the panel of 
ovarian cancer cell lines, with all but the OVCAR-4 and OVACR-8  LC50 values being below 10 
µΜ.  The best activities were for the OVACR-3 (GI50 = 1.60 µΜ and LC50 = 5.43 µΜ) and SK-
OV-3 (GI50 = 1.60 µΜ and LC50 = 5.43 µΜ), with the poorest activity against the OVACR-4 
(GI50 = 1.80 µΜ and LC50 = 28.5 µΜ) and OVACR-8 (GI50 = 3.08 µΜ and LC50 = 33.8 µΜ) cell 
lines.  The complete ovarian cancer cell line data for trisaccharide 19 is outlined in Table 7. 
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Table 7:  Ovarian Cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Ovarian Cancer 
cell type 
panel/cell line 
GI 50 TGI LC50 
IGROV1 
1.62 3.32 6.81 
 
OVCAR-3 
1.60 2.95 5.43 
OVCAR-4 
1.80 7.83 28.5 
 
OVCAR-5 
1.89 3.73 7.38 
OVACR-8 
3.08 11.2 33.8 
 
SK-OV-3 
1.60 2.95 5.43 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
The trisaccharide 19 showed variable potency against the panel of renal cancer cell lines, 
with  LC50 values ranging from10 µΜ to 51.5 µΜ.  The best activities were for the UO-31 (GI50 
= 1.49 µΜ and LC50 = 5.30 µΜ), with the poorest activity against the 786-0 (GI50 = 5.10 µΜ and 
LC50 = 40.6 µΜ) and A498 (GI50 = 1.37 µΜ and LC50 = 51.5 µΜ) cell lines.  The complete Renal 
cancer cell line data for trisaccharide 19 is outlined in Table 8. 
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Table 8:  Renal Cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Renal Cancer 
cell type 
panel/cell line 
GI 50 TGI LC50 
786-0 
5.10 16.5 40.6 
 
A498 
1.37 2.66 51.5 
ACHN 
1.83 3.92 8.39 
 
CAKI-1 
1.97 5.98 22.3 
RXF-393 
1.53 3.44 7.74 
 
SN12C 
1.94 4.53 11.5 
 
TK-10 
2.30 6.46 23.1 
 
UO-31 
1.49 2.81 5.30 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
Although it only contains two cell lines, the trisaccharide 19 showed excellent potency 
against the panel of prostate cancer cell lines, with  LC50 values below 10 µΜ.  The best 
inhibitory activities were found for the DU-145 (GI50 = 1.81 µΜ and LC50 = 5.66 µΜ) cell lines, 
with the excellent although lower activity against the PC-3 (GI50 = 1.74 µΜ and LC50 = 9.16 µΜ) 
cell lines.  The complete prostate cancer cell line data for trisaccharide 19 is outlined in Table 9. 
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Table 9:  Prostate Cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Prostate Cancer 
cell type 
panel/cell line 
GI 50 TGI LC50 
PC-3 1.74 3.99 9.16 
 
DU-145 1.81 3.20 5.66 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
The trisaccharide 19 showed the most variable potency against the panel of breast cancer 
cell lines, with  LC50 values ranging from 5 µΜ to > 100 µΜ.  The best activities were for the 
MDA-MB-468 (GI50 = 1.24 µΜ and LC50 = 4.99 µΜ), with the poorest activity against the 
NCI/ADR-RES (GI50 = 2.53 µΜ and LC50 > 100 µΜ) and HS 578T (GI50 = 2.51 µΜ and LC50 >  
100 µΜ) cell lines. The complete breast cancer cell line data for trisaccharide 19 is outlined in 
Table 10. 
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Table 10:  Breast Cancer cell cytotoxicity evaluation of trisaccharide 19 
19 (µΜ) Breast Cancer 
cell type 
panel/cell line 
GI 50 TGI LC50 
MCF7 
1.63 3.38 7.04 
 
NCI/ADR-RES 
2.53 6.61 >100 
MDA-MB-
231/ATCC 
2.61 7.26 25.5 
 
HS 578T 
2.51 8.0 >100 
MDA-MB-435 
3.74 15.1 39.7 
 
BT-549 
10.9 23.3 49.6 
 
T-47D 
1.42 2.77 54.1 
 
MDA-MB-468 
1.24 2.49 4.99 
 GI50: the drug concentration resulting in a 50% reduction in the net protein increase in control cells.  
 TGI: the drug concentration resulting in no increase in the measured protein as compared to control cells.  
 LC50: the drug concentration resulting in a 50% reduction in the measured protein as compared to control cells. 
 
 We decided to further study the mechanism of cytotoxicity of 19 towards human H460 
lung epithelial cancer cells (Figure 7). H460 human lung epithelial cells were treated with 
trisaccharide 19 at a range of concentrations (50, 100 and 200 µM) and compared to Cisplatin at 
300 µM as a control.  To ascertain the mechanism of cell death (Figure 8), the samples were then 
stained with to dyes, propidium iodide (PI, 30 mg/ml) and 1 µg/ml Hoechst (HT, 1 mg/ml). 
Apoptotic cells appeared shrunken with condensed nuclei and stain only with Hoechst, whereas 
cells that have undergone apoptosis-dependent or apoptosis-independent necrosis stained with 
both PI and Hoechst.  By comparing these staining differences, the level of toral cell death and 
percent cell death by apoptosis can be determined. 
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Figure 7:  Cytotoxicity of 19/Cisplatin towards H460 
 
 Graph denotes total cell death (apoptosis+necrosis) observed upon treatment of H460 cells with either no drug 
(NTX), 300 uM cisplatin (CP300), 50 uM of 19 (PI-50), 100 uM of 19 (PI-100), 200 uM of 19 (PI-200). 
 
At 50 µM of trisaccharide 19, the H460 cells stained mainly for Hoechst and displayed 
condensed nuclear bodies without significant uptake of propidium iodide, suggesting that cell 
death was due primarily to apoptosis.  However, at higher concentrations of 19 (100 µM and 200 
µM), cell death predominantly occurred via necrosis, which was indicated by PI staining without 
nuclear bodies.  
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Figure 8:  Mechanism of cell death apoptosis/necrosis 
 
 H460 lung epithelial cancer cells were treated with either Cisplatin (300 µM) or 19 (50, 100 and 200 µM) for 8 h 
in serum free medium, following which each well was incubated in 30 µg/ml propidium iodide (PI) and 1 µg/ml 
Hoechst (HT) for 30 min. 
 Images show cells stained for Hoechst alone (top panel, blue), PI alone (middle panel, red), or both.  
 
 In summary, a practical route to vineomycin C/PI-080 trisaccharide 19 has been 
developed.  This route provided significant amounts of material for biological testing.  The 
trisaccharide 19 was shown to suppress the proliferation of several human cancer cell lines via an 
apoptotic mechanism at 50 µΜ.  Although it should be noted that when 19 was tested at higher 
concentrations (100 and 200 µΜ) a significant amount of necrosis was also detected. This 
synthetic/biological study establishes for the first time the importance of the trisaccharide portion 
to the SAR to these molecules.  To gain a better understanding of how the 3-D structure of 19 
relates to its biological activity, we decided to synthesize and test the (L,L,D)-enantiomer of 19 
(Figure 9),  which we believed would allow us to determine if the cytotoxicity toward the cancer 
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cells were due to specific interactions with 19 or the general toxicity of various functional groups 
like pyranones and/or PMB-ethers. 
Figure 9:  The (D,D,L)-trisaccharide 19 and the (L,L,D)-trisaccharide ent-19 
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Retrosynthetically, ent-19 was envisioned as coming from two units of ent-5(α-D) and 
one unit of ent-6(β-L).  Thus, by an identical process as described above, ent-6(β-L) can be 
converted into ent-13, which can be coupled with ent-5(α-D) to form ent-18.  Finally, ent-18 can 
be coupled with ent-5(α-D) to give ent-19, the (L,L,D)-enantiomer of trisaccharide 19. 
Scheme 8:  Retrosynthesis the enantiomer of trisaccharide ent-19 
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In practice, the synthesis of the enantiomeric series began with the glycosylation of 
PMBOH with ent-6 to give ent-9 (99% yield).  The Luche reduction of ent-9 gave a good yield 
of a mixture of allylic alcohols ent-10a/b (99% yield).  The mixture of diastereomeric alcohols 
ent-10a/b were reductively rearranged using the Myer’s procedure to give alcohols ent-11 (99% 
yield).  UpJohn dihydroxylation of ent-11 cleanly gave diol ent-12 (86% yield).  Finally the L-
olivose sugar ent-13 was prepared by the regioselective Mitsunobu invesion of diol ent-12 (70% 
yield).  
Scheme 9:  Retrosynthesis the enantiomer of monosaccharide ent-13 
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Similarly, the synthesis of the of D,L-disaccharide ent-18 began with the glycosylation of 
ent-13 with ent-6 (87% yield).  The Luche reduction of ent-14 gave the allylic alcohols ent-15 
(97% yield).  Mitsunobu inversion of ent-15 with p-nitrobenzoic acid gave the bis-nitrobenzoate 
ent-16 (74% yield).  The two esters were hydrolyzed with excess LiOH (80%) and the double 
bond was hydrogenated with excess diimide (NBSH/Et3N) to give the D,L-disaccharide ent-18.  
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Scheme 10:  Retrosynthesis the enantiomer of D,L-disaccharide ent-18 
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Finally the disaccharide ent-18 was regioselectively glycosylated with ent-5(α-D) at low 
conversion to give 40% of the desired trisaccaride ent-19 along with 50% recovered starting 
material.  Material from this synthesis was sent to NCI for evaluation in their 60 cell line screen. 
Scheme 11:  Retrosynthesis the enantiomer of trisaccharide ent-19 
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In conclusion, a highly enantioselective de novo route to vineomycin C/PI-080 
trisaccharide 19 and its enantiomer (ent-19) has been achieved.  The trisaccharide 19 was 
extensively studied as an anti-cancer agent as well as mechanism of action studies.  These studies 
demonstrated 19’s ability to suppress the proliferation of several human cancer cell lines via an 
apoptotic mechanism at 50 µΜ, which demonstrated for the first time that the sugar portion of 
these type of natural products can contribute to its anti-cancer activity.  It should be noted that 
when 19 was tested at higher concentrations (100 and 200 µΜ), a significant amount of necrosis 
was also detected, which may suggest its cancer cell toxicity may occure via multiple modes of 
action.  To further explore the mechanism of action a synthesis of ent-19 was undertaken.  The 
synthesis of the ent-19 was also completed and samples were submitted to NCI for biological 
evaluation.  The preparation of the other diastereomers and further biological investigation are 
ongoing. 
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Chapter II.  Application of De Novo Syntheis Towards the Synthesis of  
C-Aryl Glycoside Natural Products 
Building on the successful synthesis of the trisaccharide portion of PI-080/Vineomycin C, 
we decided to next try to explore new methods for installing the C-Aryl glycoside portion of PI-
080 and Vineomycin C.  This was initially envisioned as being a model study, however, it was 
hoped that these efforts would eventually lead to the first synthesis of Vineomycin C.  At the 
outset, we were aware of the successful syntheses of Vineomycinone B2 methyl ester by others 
and believed that our previously described methodology could be used to install the remaing two 
sugars (Scheme 12).6-9  Instead, we decided to focus on trying to develop method for constucting 
the crutial β-linked glycosidic bond between the fully constructed trisaccharide and the aglycon.   
Scheme 12:  Retrosynthetic analysis for vineomycin C  
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This approach, if successful, in addition to being more efficienet due to convergency, 
would also be more amenable for the synthesis of a larger range of natural products from this 
family (e.g., both Vineomycin C and PI-080).10,11  As outlined in Scheme 13, we envisioned 
direct coupling of the Vineomycin C/PI-080 trisaccharide 21 with an anomeric leaving group, 
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with a suitably protected aglycon 22.  We imagined this step would be promoted by a Lewis acid.  
The exact nature of the right Lewis acid and protecting groups would need to be explored, but 
there were significant precedents from the syntheses of Vineomycinone B2 methyl ester that we 
thought we could build upon.6,9 
Scheme 13:  Retrosynthetic analysis for vineomycin C  
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 By a related route, the syntheses of more complicated angucycline structures could also 
be accomplished (Schemes 14 and 15).  Our synthesis of PI-080 was imagined as being 
completed by an annulation of the napthalene trisaccharide 23 with 24.  In turn, 23 was 
envisioned as coming from the above described convergent glycosylation between trisaccharide 
25 and napthalene 26. Similalry, the slightly simplers angucycline natural products SCH-47554 
and SCH-4755524 could be derived by an annulative coupling of the napthalene disaccharide 27 
with 24, where once again the disaccharide 27 was seen as coming from a Lewis acid mediated 
coupling between 26 and a disacchairde 28.  Recently a route to a molecule similar to 
disaccharide 27 was reported by Barrett.25  The Barrett route prepared its disaccharide in 21 total 
steps from D-glucose and L-rhamnose.  Thus as a goal we set out to try to prepare a similar 
disaccharide to 27 via our de novo methodology in significantly less steps from 2-acylfuran. 
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Scheme 14:  Retrosynthetic analysis for PI-080  
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 For simplicity sake, we decided to focus our methodology on the development of this 
latter coupling reaction between 26 and 28 (Scheme 15).   Because we already had access to 
trisaccharide 19, the investigation of the coupling between 25 and 26 was also planned. In 
addition to the development of a new more convergent coupling strategy, it was also imagined 
that materials from these studies would lead to important SAR studies of the biological activity 
of the vineomycin and PI-080 type natural products. 
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Scheme 15:  Retrosynthetic analysis for SCH-47554 and SCH-7555  
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 Our first synthetic target became the known bromonapthalene 33, which we hoped can be 
prepared by a benzyne Diels-Alder reaction/acid catalyzed ring opening reaction sequence 
(Scheme 16).2526  While 33 was known in the literature, the literature synthesis was reported to 
occur via an unselective bromination of juvalone.27  
Scheme 16:  Synthesis of key Bromoanthracene coupling partner 
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We decided to explore the route outlined in Scheme 16.  This was accomplished by 
treating 2,5-dibromo-1,4-dimethoxybenzene 31 with LDA followed by furan at –78 °C, which 
led to the formation of Diels-Alder adduct 32 in a near quantitative.  Acid-catalyzed 
rearrangement of 32 cleanly gave 33 in an excellent yield (94%).  Key to the success of this 
strategy was the ability of the bromine atom to direct the furan ring opening reaction.  There had 
been precedent in the literature of methoxy-groups and fluorides but not bromines. 
Scheme 17:  Synthesis of the D-amiceto-sugar of the desired disaccharide 38 
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 We next turned to the synthesis of the desired D,L-disaccharide 38, with a pivaloate ester 
as the anomeric leaving group (Scheme 17).  We initially looked into using a t-butyl carbonate as 
the anomeric leaving group but it proved to be too unstable.  Because we were concerned about 
the potential instablilty of the pyranone ring system to the proposed Lewis acid β-C-glycoside 
forming conditions, we also planned on making the allylic acetate 39, which in turn can be 
deprotected and oxidized to the pyranone. 
The syntheis of 38 began with the synthesis of α-pyranone 35. As before, the 
Achmatowicz oxidation of (ent)-7 formed hemi-acetal 34 as a mixture of diastereomers (Scheme 
17), which was diastereoselectively acylated with pivalolyl chloride to give 35 (82% yield).  
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Luche reduction (NaBH4/CeCl3) of pyranone 35 diastereoselectiely gave allylic alcohol 36 (68% 
yield), which was followed by a diimide reduction (excess NBSH/Et3N) of the pyran double 
bond to give 37 (80%). Our investigation into a cobalt catalyzed one-pot concomiant 1,4-/1,2-
reduction of the enone of 35 to the equatorial alcohol of 37 led only to decompisition.  
Scheme 18:  Synthesis of the D,L-disaccharides 38 and 39 
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We returned to the palladium glycosylation condition to install the L-sugar of the desired 
disaccharides 38 and 39 (Scheme 18).  Exposure of 37 to a slight excess of Boc-pyraone 5(α-L) 
and Pd-catalysis (2.5% Pd2(dba)•CHCl3/10% PPh3) gave good yield of 38 (70% yield). Finally, 
another Luche reduction (NaBH4/CeCl3) of pyranone 38 followed by acylation (Ac2O/DMAP) 
gave the backup disaccharide 39 in 70% for the two steps. 
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Scheme 19:  Attempted Lewis coupling of 38 and 39 with 33 
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With the model napthanol 33 and the two D,L-diassacharides 38 and 39 in hand, we 
explored the use of various Lewis acid (TiCl4, Ti(Oi-Pr)4, SiCl4, BF3, and TMSOTf) to promote 
coupling (Scheme 19).  Unfortuantley, all the Lewis acids used for the coupling of 33 and the 
D,L-diassacharides 38 led to decomposition of the disaccharide 38. Similarly, when the D,L-
diassacharides 39 was used, the only coupling products detected were of mono-saccharides with 
33.   
Despite these frustrations, we decided to go ahead and explore the coupling of 33 with 
the vineomycin trisaccharide 19 (Scheme 20).  In an attempt to address the problems associated 
with the instability of the glycosidic bonds to the harsh Lewis acid conditions that are required 
for the coupling reactions, we decided to first preassociate the two coupling partners via an O-
glycoside bond (44) and persue condition for migration of the trisaccharide from oxygen to 
carbon (44 to 45), which we hoped would allow for the use of milder Lewis acids. 
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Scheme 20:  Synthesis of the vineomycin C/PI-080 trisaccharide 43 coupling partner 
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To prepare the trisaccharide 19 for the coupling reaction, we first protected the C-3 
olivose sugar alcohol as an acetate and deprotected the C-1 OPMB group.  This was 
accomplished by using acetic anhydride and DMAP to give 20 (82%).  To our surprise the 
deprotection of the anomeric PMB group with ceric ammonium nitrate occurred with 
conconiment acetate deprotection.  Fortuantely, this problem was easily solved by switching to 
DDQ condition.  These modified conditions led to clean conversion of 20 to 43 (82%) as a 
mixture of anomeric isomers. 
With  43  in hand, we turned our attention to its coupling with 33 to initially form the O-
glycoside 44, and eventually its conversion to the desired C-glycoside 45.28  The efforts to 
assemble the bond began with the attempts to in situ convert the anomeric alcohol to a good 
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leaving group (tosylate) followed by an SN2 type displacement with the phenoxide anion from 33.  
While we attempted with several bases (Py, Et3N, NaH, KOt-Bu), unfortunately no desired 
product was detected. In contrast, the desired O-glycoside 44 was formed as a mixture of 
anomeric diastereomers in good yield when we turned to typical Mitsunobu conditions 
(PPh3/DIAD). Unfortunately, all attempts to use Lewis acids to isomerize the O-glycoside 44 
into the desire β-link C-glycoside led to either no reaction or decompostion of 44. 
Scheme 21:  Attempted coupling of 33 with 43 
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In conclusion, a new synthesis of the disaccharide portion of the C-aryl glycoside natural 
products SCH-47554 and SCH-47555 was accomplished. In addition, two methods were 
explored for the Lewis acid directed formation of β-linked C-aryl di- and tri-saccharides.  The 
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first was the direct Lewic acid coupling and the second was the Lewis acid promoted migration 
of O- to C-glycosides. Unfortunately neither method led to the desired product.  It is worth 
noting that if we were successful in our coupling stragy to make disaccharide 40 we would have 
achieve our goal to beat the Barrett route by 11 steps (10 vs 21 total steps). Future efforts will 
focus on the use of other aromatic rings in the Lewis acid promoted migration of O- to C-
glycosides.    
38 
 
Chapter III. Attempted Synthesis of Glycosylated Poly-Aromatic Natural 
Products  
 
In contrast to the focus of the previous chapters, the focus of this chapter is the 
development of a new method for installing natural and unnatural sugars onto known poly-
aromatic natural products.  In the previous chapters, we demonstrated that the sugar portion of 
glycosylated natural products can also be part of the natural product’s pharmacophore, as 
opposed to a water solubility enhancer. Returning to this previously believed mantra, we 
imagined installing sugars onto relatively insoluble natural products to improve its solubility.  In 
addition, we hoped that this would improve the overall activity.  The biologically active natural 
products we chose for these efforts were ellipticines29 and camptothecins30 (Figure 10). 
Figure 10: Ellipticine and related compounds 
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Both ellipticines and camptothecins are angular, albeit flat poly-aromatic alkaloids that 
contain a pyridine ring.31,32  The structural similarity also shows up in their biological mechanism 
of action.  Both natural products intercalate into DNA and have basic groups that hydrogen bond 
to DNA.  This DNA binding causes the inhibition of the DNA-repair enzymes, topoisomerase I 
or topoisomerase II.29,30,33  Inhibition of topoisomerase I and topoisomerase II has been linked to 
selective toxicity to various cancer cells, and could possibly lead to a new treatment for cancer.  
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While neither ellipticine nor camptothecin has become an approved drug, two related 
camptothecins (topotecan and irinotecan, Figure 12) have been approved for use as cancer 
chemotherapeutics.29,30 For our first foray into the synthesis of glycosylated variants of these 
types of natural products, we decided to look into the synthesis of glycosylated ellipticines 
because of the overall simpler structure. These glycosylation studies required the preparation of 
various hydroxy-substituted aza-ellipticines.34 
Figure 11: Ellipticine and related compounds 
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Ellipticine (5,11-Dimethyl-6H-pyrido[4,3-b]carbazole) is a tetracyclic indole/pyridine 
containing natural product that has attracted significant attention for its potential as an 
antineoplastic agent.35  Structurally related natural products, like 9-methoxy-ellipticine33 and 5-
aza-ellipticine,36 have also been isolated and show significant anti-cancer activities (Figure 11). 
The mode of action for the ellipticines has been found to occur by binding to the DNA repair 
enzyme topoisomerase II. Unfortunately, issues associated with overall toxicity have limited the 
interest in the use of these natural products as drugs. That being stated, significant interest in 
synthesizing and testing of analogue structures of ellipticine still remains active. In this regard, 
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we felt that glycosylated ellipticines, in addition to having better water solubility (lowering it 
effective dose), may lead to selective uptake by cancer cells. 
Scheme 22: The Wang cyclization approach to ellipticine 
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In a similar effort to prepare more active ellipticine analogues, the Wang group has 
developed a route to related 5-aza-ellipticines (Scheme 22).37  This route utilizes a Wang or bis-
aza-Schmittel type cyclization (46 to 48)38,39 to establish the aza-ellipticine ring system.  The 
Wang approach to the ellipticine replaces the allene portion of the Schmittel substrate with a 
carbodiimide functional group, and is believed to occur via a bi-radical intermediate, like 47. We 
decided to use this approach to prepare aza-ellipticine substrates for glycosylation. 
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Scheme 23:  Hydroxylated 5-aza-ellipticines for potential glycosylation 
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To allow for glycosylation, we need access to aza-elipticines substituted with hydroxyl 
group. To maximize the range of reactivity in the glycosylation reaction, we planned to install 
both phenolic and benzylic hydroxyl groups.  We desired aza-ellipticines 52 and 53 for our 
glycosylation studies and targeted their syntheses with the appropriate protecting groups 
(Scheme 23). Our retrosynthetic plan for the target molecule 54, with R1 being a protected 
phenol and R2 being either a hydrogen or a protected alcohol, is outlined in Scheme 24.  We 
chose to use a benzyl ether and a trialkyl silyl ether as orthogonal protecting groups.  Because we 
were more confident with the stability of the benzyl ether to the thermal conditions of the Wang 
cyclization, we chose to make aza-ellipticines with R1 = BnO and R2 = H or R3SiO (54, Scheme 
24). 
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Scheme 24:  Retrosynthesis for a Hydroxylated aza-ellipticines 
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Our first effort to prepare a hydroxylated aza-ellipticine is outlined in Scheme 25 and was 
based on a route previously developed by Quan Zhang, Chongsheng Shi, Hai-Ren Zhang, and 
Prof. Wang.37 The synthesis began with protection of the more reactive C-4 phenol in 
commercially available methyl 2,4-dihydroxybenzoate 60. Using the Williamson ether 
conditions (K2CO3/BnBr), the C-4 phenol was converted to the benzyl ether 61 in an 86% yield.  
The remaining C-2 phenol was converted into the aryltriflate 62 with Tf2O/Py in near 
quantitative yield.  Sonogashira coupling of triflate 62 with excess propyne gave 63 in good yield.  
Base-catalyzed hydrolysis of the methyl ester 63 gave the desired carboxylic acid 64 after 
acidification.  It should be noted that the ester hydrolysis reaction needed to be carefully 
monitored because of a competing alkyne hydrolysis reaction giving ketone 65, which at times 
could be quite significant.  The optimal reaction condition was to carefully monitor the reaction 
by TLC and to quench the reaction at the first sign of ketone formation. 
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Scheme 25:  Synthesis of the key alkynyl acid 
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With the alkynyl acid 64 in hand, we next looked into the conversion of it to isocyanate 
67 via Curtius rearrangement (Scheme 26).  Exposure of carboxylic acid 64 to phosphoryl azide 
66 cleanly gave 67 in good yields without the use of silica gel chromatography.  It should be 
noted that using pH 7 water in the aqueous work up of the reaction is important to prevent 
hydrolysis of the acyl azide 67 back to the carboxylic acid 64.  Finally, thermolysis of the acyl 
azide 67 in refluxing toluene cleanly gave isocyanate 68, which in turn could be used without 
further purification.  
Scheme 26:  Synthesis of the key isocyanate 
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 Finally, the isocyanate 68 was converted into the desired 9-benzyloxy-5-aza-ellipticine 71 
via the Wang cyclization (Scheme 27).  Isocyanate 68 was treated with freshly prepared 
phosphoryl imine 69.40 After the evidence of carbodiimide 70 formation was indicated by TLC, 
the reaction was heated at 138 °C for 15 h to give the desired aza-ellipticine 71 in 25% overall 
yield. Pure aza-ellipticine 71 was isolated by a cumbersome extraction/precipitation sequence, 
instead of silica gel chromatography, due to its poor solubility. 
Scheme 27:  Synthesis of a Hydroxylated aza-ellipticines 
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The final hydrogenolysis deprotection of benzyl-protected hydroxy-aza-ellipticine failed 
in many solvents (Scheme 28).  The same solubility problem that made the purification of 71 
quite difficult also limited our ability to further functionalize 71. Ellipticine 71 was only soluble 
in polar protic solvent like acidic acid.  In fact, the hydrogenolysis of 71 in acetic acid may have 
worked. The starting material disappeared by TLC, but no recognizable products were isolated 
from the reaction.  This may have been due to the limited solubility of the product, but also 
potentially due to the instability of the product 72 (i.e., oxidation of the phenol 72 to an aza-
quinone).  Thus, we desired an alternative route to different aza-ellipticine. 
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Scheme 28:  Attempted deprotection of the benzyl ether 
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Our next route envisioned the installation of a TBS-protected benzylic alcohol for 
eventual glycosylation.  The addition of this large lipophilic functional group may also improve 
the solubility of the product. Once again, this route ran into problems with protecting group 
chemistry.  In particular, problems were experienced with the instability of a TBS-group during 
the ester hydrolysis step. Later on in this chapter, a similar problem was encountered with a 
TIPS-group falling off during a Wang cyclization (Scheme 30). 
This revised route returned to the Sonogashira coupling of triflate 62, but now with TBS-
protected propargyl alcohol instead of propyne (Scheme 29).  While a Sonogashira reaction 
worked to give an 81% yield of the desired alkynyl ester 74, all our attempts to hydrolysis the 
methyl ester 74 occurred with concomitant hydrolysis of the TBS-ether. 
Scheme 29:  Synthesis of a Hydroxylated aza-ellipticines 
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Thus, we decided to switch to the bulkier TIPS-protecting group (Scheme 30). Although 
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the Sonogashira coupling between triflate 62 and TIPS-protected propargyl alcohol failed, we 
were able to couple the triflate 62 with the unprotected propargyl alcohol to give 75 in good 
overall yield, which then was protected with TIPS-chloride in near quantitative yield to give 
TIPS-ether 76. 
Scheme 30:  Synthesis of a Hydroxylated aza-ellipticines 
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Now with the TIPS group in place (Scheme 30), we were able to selectively hydrolyze 
the methyl ester 76 with LiOH and isolate the carboxylic acid 77 in 55% yield after acidification. 
As before, we were able to convert the carboxylic acid 77 to the acylazide 78 with the 
phosphoryl azide reagent.  Similarly thermolysis of acyl azide 78 cleanly gave isocyanate 79 in 
good yield.  However, the reaction failed when we preformed the typical Wang cyclization 
procedure on isocyanate 79. When we treated isocyanate 79 with the phosphoryl imide 69 
reagent until a new spot appeared, and then heated the reaction mixture to 138 °C for several 
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hours, we were not able to isolate any product that looked like the desired aza-ellipticine 80.  
Only TIPSOH was detected, which led us to believe that the TIPS ether was falling apart under 
these high temperatures. 
These difficulties associate with the poor solubility of the aza-ellipticines convinced us to 
switch our starting natural product of focus to the camptothecins.  We chose the camptothecins 
because they share many similar features with the ellipticines.  These similarities include: 1) both 
are poly-aromatic anti-cancer agent, 2) both cytotoxicities result from the inhibition of 
topoisomerase (I and II), and 3) both potential as a drug candidate suffer from poor solubility.   
Evidence in the literature suggests that camptothecins display a slightly better solubility profile 
in aprotic solvents. It should be noted that much of this evidence was collected from the patent 
literature, which more often than not, did not report experimental procedures and/or spectral data.  
Figure 12:  Camptothecin and related structures 
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 Camptothecin is a naturally occurring highly conjugated polycyclic quinoline that has 
been attracting a tremendous amount of attention from both the academia and the pharmaceutical 
industry.41  Since its initial isolation in 1966 from the Chinese plant Camptotheca acuminata,42 
the alkaloid has shown excellent antitumor activity.   In fact, several camptothecin analogues are 
being used clinically for treatment of various cancers (Figure 12).43 
It is worth noting that in the 1970s camptothecin was entered into clinical trials in the form 
of its water-soluble sodium salt of the hydrolyzed ester; however, the trials failed and the interest 
in camptothecin subsided.  Revived interest in camptothecin came from the discovery of its 
mechanism of action.44  In the late 1980s, it was discovered that camptothecin interacts with 
DNA topoisomerase I, an enzyme that is essential for DNA replication.45  The topoisomerases are 
enzymes that catalyze the topo-isomerization reactions (relaxation/supercoiling, 
knotting/unknotting and catenation/decatenation) of DNA.46  In fact, the structure of the 
cleavable ternary complex is of great interest for the elucidation of the mechanism of action and 
development of new topoisomerase inhibitors.  The discovery of topoisomerases as new targets 
for cancer chemotherapy and the mechanism of action of camptothecin put camptothecin back on 
the frontlines of anticancer drug development.47  As the result of these renewed efforts, two FDA 
approved drugs have appeared on the market topotecan (ovarian cancer and small-cell lung 
cancer) and irinotecan (colorectal cancer).48 
Besides ongoing studies on topotecan and irinotecan, significant effort has also been 
spent on the development of new anticancer drugs from this family, with a particular effort 
towards producing compounds with better solubility and tissue-targeting properties.49  To these 
ends, we proposed to take advantage of the inherent water solubility of carbohydrates, along with 
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the fact that they are actively transported across cell membranes to make new carbohydrate-
linked camptothecin analogues. It should be noted that the problems associated with the use of 
camptothecins are primarily related to its poor solubility in both organic solvents and water.   
Scheme 31:  The Wang approach to camptothecin 
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More recently, the Wang group developed a new synthetic pathway to the camptothecin 
ABCD ring system (Scheme 31).50  The Wang approach begins with the N-alkylation of 1,6-
dihydro-6-oxo-2-pyridinecarbonitrile 81 to provide 82.  Treatment of 82 with a catalytic amount 
of DBU (5 mol %) at 110 °C for 12 hours produced the desired ABCD ring core of camptothecin 
85.  Key to the Wang approach is the recognition that a base-catalyzed isomerization of alkyne 
82 to 83, which in turn will undergo a cycloadditon to give 84, followed by a 1,5-proton 
migration to give 85.  While there are many approaches to this natural product,51 none of these 
approaches could compare to the Wang route in terms of overall efficiency and flexibility. 
As a prelude to the eventual glycosylation of synthetic hydroxy-substituted 
camptothecins from the above route, we decided to work with the natural product instead.  We 
could do this because camptothecin already has a hydroxyl group and is commercially available, 
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albeit expensive. This idea was drawn from the fact that nature already produced a glycosylated 
camptothecin (see gluco-camptothecin, Figure 12), which had also shown improved biological 
activity, presumably as a pro-drug.  That is to say, the glucose must be hydrolyzed before the 
camptothecin can bind to DNA.   
Scheme 32:  Attempted glycosylation of the tertiary hydroxyl of Camptothecin 
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Encouraged by the fact that the tertiary alcohol of camptothecin can be glycosylated in 
nature, we began our efforts with the attempt to use our palladium-catalyzed glycosylation 
reaction on the tertiary alcohol of camptothecin (Scheme 32).  Unfortunately, these reactions 
failed.  We believed this was primarily due to the poor solubility of camptothecin in most 
organic solvents.  The only non-protic solvent we were able to get camptothecin to dissolve into 
was refluxing acetic anhydride, which could not be used in the glycosylation reaction. 
We attributed this lack of reactivity to solubility, instead of reactivity, because the related 
camptothecin SN-38 (Scheme 33) has a much more reactive phenol that also did not react, 
presumably due to the poor solubility in DMF. This poor solubility also inhibited our efforts to 
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functionalize the pyridine ring in camptothecin by an N-oxide to pyridone rearrangement reagent 
(e.g., 88 to 89, X = OH, Scheme 34).  
Scheme 33:  Attempted glycosylation of the phenolic OH of SN-38 
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Based on these results, we decided to install sugars via a Sonogashira reaction with 
glycosylated propargyl alcohols (Scheme 34).  We chose to prepare a camptothecin with a C-11 
leaving group for palladium cross coupling partner (e.g., 89, X = Cl, Br, I, OTf). This effort 
began with the attempted synthesis of known C-11-substituted camptothecins with either a 
hydroxyl or triflate group.  Unfortunately, this effort failed with our inability to purify the highly 
insoluble and unstable camptothecin N-oxide 88.  
Improved solubility of the camptothecins came with the acylation of the tertiary alcohol, 
which after acylation could be oxidized and rearranged to the desired C-11 chloro-pyridine.52 
Acylation of the C-4 tertiary hydroxyl group of camptothecin was accomplished by exposing 
camptothecin with l equiv of LiBr in refluxing acetic anhydride to provide good yield of 
camptothecin acetate 90 (92% yield).53  This more soluble substrate could be oxidized with 
excess mCPBA in refluxing EtOAc/CH2Cl2 to give a good yield of the N-oxide 91 (quantitative 
yield). The N-oxide 91 was unstable to silica gel chromatography, however, reasonably pure 
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material could be prepared by aqueous base extraction of the excess acid and re-crystallization. 
The N-oxide 91 was converted to the C-11 chloride 92 by exposure of a DMF/CH2Cl2 solution to 
oxalyl chloride in 76% yield.54 
Scheme 34:  Attempted synthesis of 11-substituted Camptothecin for Sonogashira coupling‡ 
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With chloride 92 in hand, we next investigated its use in the Sonogashira coupling 
reaction with various propargyl alcohols (Scheme 35). This effort built on the work of Lu and 
co-workers,55 who demonstrated the use of 7-chloro-camptothecin 92 in the Buchwald copper-
free Sonogashira coupling reaction.56  Exposing 7-chloro camptothecin 92 with THP-protected 
propargyl alcohol to catalytic Pd(OAc)2/BINAP in refluxing toluene gave good yields of alkyne 
94 (75% yield).  
                                                
‡ While the compounds in Scheme 34 are known compounds in the patent literature, their experimental and 
spectral details were not included, see, ref. 52. 
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While this route worked for very simple substrates like THP-protected propargyl alcohol 
93, it failed to give adequate amount of pure products for our desired glycosylated propargylic 
alcohol coupling partners. When we exposed our glycosylated propargyl alcohols 95-97 to the 
same Sonogashira coupling conditions, only trace amount of the desired product was detected for 
the coupling reaction with 97. Evidence of the slightly successful coupling reaction between 92 
and 97 was seen when the crude reactions products were compared to authentic material (99, 
Scheme 36).   
Scheme 35:  Attempted synthesis of glycosylated Camptothecin via Sonogashira coupling 
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With the lack of success with the more convergent Sonogashira coupling strategy, we 
turned to an alternative protocol for the synthesis of glycosylated camptothecin, like 99.  This 
began with the acid-catalyzed deprotection of the THP-group to give propargyl alcohol 98 (95% 
yield). Using our palladium catalyzed glycosylation of propagyl alcohol 98 with the β-pyranone 
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6, we were able to convert 98 in to pyranone 99.  Unfortunately, the less stable β-pyranone 
isomerized upon silica gel chromatography, which caused difficulty in separating the mixture of 
diastereomers at the anomeric position (65%). 
Scheme 36:  Attempted synthesis of glycosylated Camptothecin via Sonogashira coupling 
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Finally, a successful effort to prepare a glycosylated camptothecin came when we 
acylated the tertiary alcohol of SN-38 (Scheme 37).  This acetate group imparted improved 
solubility to the camptothecin substrate.  Unfortunately, due to the greater reactivity of phenol 
groups, a two-step acylation/deacylation sequence was needed to acylate the less reactive tertiary 
alcohol (Scheme 37).  Thus both the phenol and tertiary alcohol were acylated with acetic 
anhydride to give diacetate 101 (65% yield). The more reactive phenol was then removed with 
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MeOH/Et3N to give the desired mono-acetate 102 (50% yield).  Alternatively, the more reactive 
phenol could be protected with a TBS group to give 103 in excellent yield (83%).  Then the 
tertiary alcohol was acylated to form 104 (92%).  Finally, a TBS deprotection with HF/Py gave 
the desired phenol 102 (92%).  On small scale this later route was the higher yielding, but upon 
scale up, problem occurred with the formation of diacetate under the acylation conditions.54 
Scheme 37:  Synthesis of a more soluble analogue of SN-38 
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Finally, with the acylated SN-38 102 in hand, we were able to perform the desired Pd-
catalyzed glycosylation. This was performed with both the pyranone 5 and allylic alcohol 106 as 
π-allyl-precursors. Unfortunately, the pyranone glycosylation product 105 was not very stable, 
and had to be reduced to allylic alcohol 107 without further purification (~50%).  Alternatively, 
the allylic alcohol product 107 could be prepared in better overall yield when 102 was 
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glycosylated with 106 (83%). While more stable than 105, the allylic alcohol 107 was still 
unstable to acidic conditions. Allylic alcohol 107 smoothly underwent dihydroxylation when it 
was exposed to the typical Upjohn conditions to provide rhamno-SN-38 108 (85%).  While the 
glycosylated camptothecin 108 was significantly more stable than 105 and 107, it slowly 
underwent methanolysis to form the free aglycon 102 and methyl rhamno-pyranoside upon 
standing in methanol. Because of the expense of the SN-38 and overall instability of 
glycosylated product 108, we decided not to pursue the synthesis of further glycosylated 
camptothecin analogues. 
Scheme 38:  Successful synthesis of a glycosylated Camptothecin SN-38 
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Scheme 39:  Reason for potential instability of glycosylated SN-38 
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While it was not thought to be a major problem at the outset, the base instability of 
pyranone 105 and the acid instability of 107 and 108 were not without precedent (Scheme 39).  
For instance, it is well known that pyranones, like 105, with good leaving groups at the C-1 
position, decomposes in the presence of a base to give 1,3-dipole intermediates like 110. The 
basic nature of the pyridine ring in the camptothecin aglycon can lead to its protonation, making 
it a much better leaving group, which makes both 107 and 108 more prone to acid-catalyzed 
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hydrolysis (107 to 112 and 108 to 113). Due to the presence of the double bond, it is not 
surprising that 107 is more sensitive to acid hydrolysis than 108. 
In conclusion, we have shown that glycosylated camptothecin can be made, but their 
syntheses can be complicated by issues associated with poor solubility of the ring system.  This 
solubility problem was a bigger issue in synthesis of aza-ellipticines, such that it prevented the 
synthesis of the desired hydroxy-aza-ellipticine substrates for our proposed glycosylation studies. 
Scheme 40:  Future goals 
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 While the acid sensitivity of glycosylated SN-38 (108) will limit its use as a drug, we 
believe that future efforts in this regard could include the synthesis of cylictol analogues like 114. 
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Chapter IV. Experimental Section 
A. General methods and materials: 
1H and 13C spectra were recorded on 270 MHz and 600 MHz spectrometers. Chemical shifts 
were reported relative to benzene-d6 (δ 7.16 ppm), CDCl3 (δ 7.26 ppm), CD3OD (δ 3.31 ppm), 
acetone-d6 (δ 2.05 ppm), D2O (δ 4.80 ppm) for 1H, and benzene-d6 (δ 127.68 ppm), CDCl3 (δ 
77.0 ppm), CD3OD (δ 49.15 ppm), and acetone-d6 (δ 29.92 ppm) for 13C. Optical rotations were 
measured with a digital polarimeter in the solvent specified. Infrared (IR) spectra were obtained 
on a FT-IR spectrometer. Flash column chromatography was performed on 60-200 mesh silica 
gel. Analytical thin-layer chromatography was performed with precoated glass-backed plates and 
visualized by quenching of fluorescence and by charring after treatment with p-anisaldehyde or 
phosphomolybdic acid or potassium permanganate stain. Rf values were obtained by elution in 
the stated solvent ratios (v/v). Ether, THF, methylene chloride, toluene and triethylamine were 
dried by passing through activated alumina (8 x 14 mesh) column with argon gas pressure. 
Commercial reagents were used without purification unless otherwise noted. Air and/or 
moisture-sensitive reactions were carried out under an atmosphere of argon/nitrogen using 
oven/flamed-dried glassware and standard syringe/septum techniques. 
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B: Experimental Procedures for Chapter I: 
(R)-1-(furan-2-yl) ethanol (7(R))§  
O
OH
 
To a 250 mL flask was added furan ketone 8 (22 g, 0.2 mol), CH2Cl2 (100 mL), formic 
acid/triethylamine (1:1, 108 mL) and Noyori asymmetric transfer hydrogenation catalyst (R)-
Ru(η6-mesitylene)-(R,R)-TsDPEN (585 mg, 0.5 mol%). The resulting solution was stirred at 
room temperature for 24 h. The reaction mixture was diluted with water (150 mL) and extracted 
with Et2O (3 x 150 mL). The combined organic layers were washed with satd. aq. NaHCO3, 
dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by 
silica gel flash chromatography eluting with 20% Et2O/hexanes to give furan alcohol 7(R) (21.5 
g, 0.19 mmol, 96%) as a colorless oil; Rf (30% Et2O/hexanes) = 0.24; [α]
21  D  + 20.8 (c 1.20, 
CHCl3); IR (thin film, cm-1) 3361, 2979, 2934, 1669, 1504, 1465, 1371, 1230, 1148, 1008, 878, 
735; 1H NMR (270 MHz CDCl3) δ 7.37 (d, J = 1.8 Hz, 1H), 6.32 (dd, J = 3.2, 1.8 Hz, 1H), 6.22 
(ddd, J = 3.2 Hz, 1H), 4.87 (q, J =6.5 Hz, 1H), 2.25 (bs, 1H), 1.53 (d, J = 8.0 Hz, 3H); 13C NMR 
(67.5 MHz, CDCl3) δ 158.0, 142.3, 110.5, 105.5, 64.0, 21.7. 
                                                
§ Spectral data matches that for previously reported material, see: Shan, M.; O’Doherty, G. A. Org. Lett. 2006, 8, 
5149-5152. 
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(S)-1-(2-Furyl)-ethanol (7(S)):§  
O
OH
 
To a 250 mL flask was added furan ketone 8 (8 g, 72.7 mmol), CH2Cl2 (37 mL), formic 
acid/triethylamine (1:1, 100 mL) and Noyori asymmetric transfer hydrogenation catalyst (R)-
Ru(η6-mesitylene)-(S,S)-TsDPEN (222 mg, 0.5 mol%). The resulting solution was stirred at 
room temperature for 24 h. The reaction mixture was diluted with water (100 mL) and extracted 
with Et2O (3 x 100 mL). The combined organic layers were washed with satd. aq. NaHCO3, 
dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by 
silica gel flash chromatography eluting with 20% Et2O/hexanes to give furan alcohol 7(S) (7.82 
g, 69.8 mmol, 96%) as a colorless oil; Rf (30% Et2O/hexanes) = 0.24; [α]
21  D   -20.1 (c 1.0, CHCl3); 
IR (thin film, cm-1) 3360, 2980, 2935, 1668, 1505, 1467, 1370, 1229, 1149, 1007, 877, 734; 1H 
NMR (270 MHz CDCl3) δ 7.37 (dd, J = 1.6, 0.8 Hz, 1H), 6.32 (dd, J = 3.2, 1.8 Hz, 1H), 6.23 
(ddd, J = 3.2, 0.8, 0.8 Hz, 1H), 4.78 (dq, J =3.4, 6.1 Hz, 1H), 2.07 (bs, 1H), 1.54 (d, J = 6.5 Hz, 
3H);  
13
C NMR (67.5 MHz, CDCl3) δ 157.7, 141.6, 109.9, 104.9, 63.3, 21.1.  
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(2R)-6-Hydroxy-2- methyl-2H-Pyran-3 (6H)-one (34): §  
O
O
CH3HO  
Furan alcohol 7(R) (9.0 g, 79.5 mmol), 100 mL of THF, and 25 mL of H2O were added to a 
round bottom flask and cooled to 0 ºC. Solid NaHCO3 (13.4 g, 159 mmol), NaOAc•3H2O (10.8 g, 
79.5 mmol), and NBS (14.9 g, 83.48 mmol) were added to the solution and the mixture was 
stirred for 1 h at 0 ºC. The reaction was quenched with satd. aq. NaHCO3 (200 mL), extracted (3 
x 200 mL) with Et2O, dried (Na2SO4), concentrated under reduced pressure and purified by silica 
gel chromatography eluting with 35% EtOAc/hexanes to give pyranone 34 (9.67 g, 75.5 mmol, 
95%, α:β =2.6 :1): Rf (60% EtOAc/hexanes) = 0.29; IR (thin film, cm-1) 3381, 2988, 2942, 1692, 
1447, 1373, 1232, 1021, 937; 1H NMR (600 MHz, CDCl3) major isomer (α): δ 6.86 (dd, J = 10.2, 
3.0 Hz, 1H), 6.04 (d, J = 10.2 Hz, 1H), 5.57 (dd, J = 4.2, 3.6 Hz, 1H), 4.66 (q, J = 6.6 Hz, 1H), 
4.36 (d, J = 5.4 Hz, 1H), 1.32 (d, J = 6.6 Hz, 3H); minor isomer (β): δ 6.91 (dd, J = 10.2, 1.8 Hz, 
1H), 6.09 (dd, J = 10.2,1.8 Hz, 1H), 5.62 (dd, J = 7.2, 1.2 Hz, 1H), 4.71(d, J = 7.2 Hz, 1H), 4.18 
(dq, J = 1.2, 6.6 Hz, 1H), 1.39 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3) major isomer 
(α): δ 197.4, 144.9, 126.9, 87.4, 70.3, 15.2. Minor isomer (β): δ 196.8, 148.5, 128.2, 87.2, 90.8, 
75.1, 16.1. 
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Tert-butyl (2S,6R)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yl carbonate ((ent)-5(α-D)) and 
Tert-butyl (2R,6R)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yl carbonate (6(β-D))** 
OBocO CH3
O
OBocO CH3
O
 
To a benzene solution (300 mL) of (5R)-1-Hydroxy-5-tert-butyl dimethylsilanyloxymethyl-5H-
pyran 4-(1H)-one A (18.5 g, 0.144 mol) and (Boc)2O (47.3 g, 0.22 mol) was added sodium 
acetate (13.2 g, 0.16 mol). After stirring at 80 °C for 2 h, the mixture was cooled down to room 
temperature. The reaction was quenched by adding of 300 mL of satd. aq. NaHCO3 solution, 
extracted (3 x 300 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure. The 
crude product was purified by silica gel flash chromatography eluting with 6 and 8% 
EtOAc/hexanes to give two diastereomers of tert-butyl 5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-
yl carbonate (29.0 g, 0.127 mol, 88%) of (ent)-5(α-D) and 6(β-D) (d.r. = 1:1.3).  
(ent)-5(α-D): Rf (20% Et2O/hexanes) = 0.43; [α]21  D = –97.1 (c 1.0, CH2Cl2); IR (thin film, cm
-1) 
2986, 1752, 1703, 1633, 1278, 1258, 1159, 1090, 1058, 1029, 944 ; 1H NMR (600 MHz, CDCl3) 
δ 6.795 (dd, J = 10.2, 4.2 Hz, 1H), 6.24 (d, J = 4.2 Hz, 1H), 6.10 (d, J = 10.2 Hz, 1H), 4.55 (q, J 
= 6.6 Hz, 1H), 1.40 (s, 9H), 1.30 (d, J = 6.7 Hz, 3H) ; 13C NMR (150 MHz, CDCl3) δ 195.4, 
151.7, 140.9, 128.1, 89.0, 83.2, 71.9, 27.4(3C), 15.0; HRCIMS Calcd for [C11H1605Na]+: 
251.0890, Found 251.0884. 
                                                
** Spectral data matches that for previously reported material, see: Zhou and G. A. O’Doherty, J. Org. Chem. 2007, 
72, 2485-2493.  
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6(β-D): Rf (20% EtOAc/hexanes) = 0.50; mp: 43-43.5 ºC; [α]21  D = + 42.3 (c 1.3, CHCl3); IR (thin 
film, cm-1) 2986, 1752, 1703, 1633, 1278, 1258, 1159, 1090, 1058, 1029, 944; 1H NMR (600 
MHz, CDCl3) δ? 6.82 (dd, J = 10.2, 2.4 Hz, 1H), 6.28 (dd, J = 2.4, 1.2 Hz, 1H), 6.11 (dd, J = 
10.2, 1.2 Hz, 1H), 4.27 (q, J = 6.6 Hz, 1H), 1.42 (s, 9H), 1.39 (d, J = 6.9 Hz, 3H); 13C NMR 
(150 MHz, CDCl3) δ? 195.6, 151.6, 142.7, 128.0, 89.7, 83.3, 75.5, 27.4(3C), 18.3; HRCIMS 
Calcd for [C11H16O5Na]+: 251.0890, Found 251.0883. 
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 (2S ,6S)-t-butyl -5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yl carbonate (5(α-L))** 
O
O
CH3BocO
5(!-L)  
Alcohol (ent)-34 (5.5 g, 42.9 mmol) was dissolved in CH2Cl2 (42 mL) and the solution was 
cooled to -78 ºC. A CH2Cl2 (2 mL) solution of (Boc)2O (13.46 g, 51.6 mmol) and a catalytic 
amount of DMAP (524.2 mg, 4.76 µmol) was added to the reaction mixture. The reaction was 
stirred for 1 h at -78 ºC, and quenched with 100 mL of satd. aq. NaHCO3, extracted with Et2O (3 
x 100 mL), dried (Na2SO4), and concentrated under reduced pressure. The crude product was 
purified using silica gel flash chromatography eluting with 6% EtOAc/hexanes to give 8.02 g 
(35.2 mmol, 82%) of two diastereomers of Boc-protected pyranone 5(α-L) and (ent)-6(β-L) in a 
ratio of 3:1. 5(α-L): Rf (20% Et2O/hexanes) = 0.58; [α]21  D  = + 98 (c = 1.0, CH2Cl2); IR (thin 
film, cm-1) 2984, 2942, 1752, 1703, 1371, 1273, 1254, 1153, 938, 838; 1H NMR (600 MHz, 
CDCl3) δ 6.78 (dd, J = 10.2, 3.6 Hz, 1H), 6.22 (d, J = 3.6 Hz, 1H), 6.09 (d, J = 10.2 Hz, 1H), 4.53 
(q, J = 6.6 Hz, 1H), 1.40 (s, 9H), 1.28 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 195.5, 
151.7, 140.9, 128.2, 89.1, 83.3, 72.0, 27.5, 15.1; ClHRMS Calculated for [C11H16O5Na+]: 
251.0890, Found: 251.0883. 
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  (2R,6R)-6-(4-methoxybenzyloxy)-2-methyl-2H-pyran-3(6H)-one (9): 
O CH3PMBO
O
 
A CH2Cl2 (2 mL) solution of tert-butyl (2S,6R)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yl 
carbonate 6(β-D) (2.28 g, 10 mmol) and 4-methoxybenzyl alcohol (2.76 g, 20 mL) was cooled to 
0 °C, Pd2(DBA)3•CHCl3 (260 mg, 2.5 mol%) and PPh3 (226 mg, 10 mol%) were added to the 
reaction mixture at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. The reaction was 
quenched by adding 10 mL of satd. aq. NaHCO3, extracted three times with ether, dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography eluting with 5% EtOAc/hexanes to give pyranone 9 (2.32 g, 9.5 mmol, 
95%) as a yellow oil:  Rf (10% EtOAc/hexanes) = 0.15; [α]21  D = -22.4 (c = 1.0, CH2Cl2); IR (thin 
film, cm-1) 2938, 2837, 1696, 1513, 1246, 1054, 1008, 818, 802; 1H NMR (600 MHz, CDCl3) δ 
7.23 (d, J = 8.4, 2H), 6.88 (d, J = 8.4, 2H), 6.83 (dd, J = 10.2, 1.2, 1H), 6.03 (d, J = 10.2, 1H), 
5.29 (d, J = 1.2, 1H), 4.79 (d, J = 11.4, 1H), 4.54 (d, J = 11.4, 1H), 4.15 (q, J = 6.6, 1H), 3.71 (s, 
3H), 1.45 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) δ 196.5, 159.2, 146.5, 129.5, 128.7, 
127.7, 113.6, 93.9, 74.9, 69.5, 54.9, 16.9; CIHRMS Calcd for [C14H16O4H]+: 249.1127.  Found 
249.1122. 
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(2R,6R)-6-(4-methoxybenzyloxy)-3,6-dihydro-2-methyl-2H-pyran-3-ol (10a/b): 
O CH3PMBO
OH
 
Pyranone 9 was dissolved in 24 mL CH2Cl2, resulting solution was cooled to -78 °C, 24 mL of 
0.4 M CeCl3 in methanol solution was added in a dropwise fashion, followed by adding 540 mg 
of NaBH4. By TLC tracking, the reaction was done after 1.5 h. The reaction mixture was diluted 
with 2 mL diethyl ether, then quenched with 2 mL water, extracted with 3 x 20 mL diethyl ether, 
dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography eluting with 80% EtOAc/Hexane to 
give allylic alcohol 10a/b as a mixture of diastereomers (2.40 g, 9.5 mmol, 99%) as a colorless 
oil: Rf (30% EtOAc/hexanes) = 0.45; [α]21  D  = -58.5 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3421, 
2977, 2871, 1612, 1513, 1244, 1172, 1031, 818, 788;  
10a 1H NMR (600 MHz, CDCl3) δ 7.26 (d, J = 8.4, 2H), 6.85 (d, J = 8.4, 2H), 6.11 (ddd, J = 
10.2, 5.4, 1.8, 1H), 5.81 (d, J = 10.2, 1H), 5.09 (m, 1H), 4.80 (d, J = 11.4, 1H), 4.56 (d, J = 11.4, 
1H), 3.77 (s, 3H), 3.68 (m, 1H), 3.64 (m, 1H), 2.00 (m, 1H), 1.30 (d, J = 6.6, 3H); 
10b 1H NMR (600 MHz, CDCl3) δ 7.26 (d, J = 8.4, 2H), 6.85 (d, J = 8.4, 2H), 5.92 (d, J = 10.2, 
1H), 5.75 (d, J = 10.2, 1H), 5.09 (m, 1H), 4.76 (d, J = 11.4, 1H), 4.52 (d, J = 11.4, 1H), 3.77 (s, 
3H), 3.71 (m, 1H), 3.68 (m, 1H), 2.00 (m, 1H), 1.35 (d, J = 6.6, 3H); 13C NMR (150 MHz, 
CDCl3) major isomer δ 159.3 (2C), 131.2 (2C), 129.7, 129.6, 113.8, 96.7, 71.5, 69.6, 68.4, 64.8, 
55.3, 16.6; CIHRMS Calcd for [C14H18O4Na]+:  273.1103.  Found 273.1100. 
68 
 
(2R,6R)-2-(4-methoxybenzyloxy)-3,6-dihydro-6-methyl-2H-pyran (11): 
O CH3PMBO  
A flask charged with dry N-Methyl morpholine (NMM) 20 mL, triphenyl phosphine (6.86 g, 
30.36 mmol) was cooled to -30 °C under argon atmosphere. Diethylazodicarboxylate (4.35 mL, 
27.6 mmol) was added and the reaction was stirred for 5 min, allylic alcohol 10a/b (2.3 g, 9.2 
mmol) was added to in a 1 M of NMM (9.2 mL), the resulting reaction mixture was stirred for 10 
min, followed by addition of o-nitrobenzenesulfonyl hydrazide (NBSH) (5.99 g, 27.6 mmol). 
The reaction was stirred at -30 °C for 2 h and was monitored by TLC.  Upon consumption of 
10a/b, the reaction was warmed to room temperature and stirred for another 2 h. The reaction 
mixture was diluted with ether (20 mL) and was quenched with 10 mL of satd. aq. NaHCO3, 
extracted (3 x 50 mL) with ether, dried over Na2SO4, and concentrated under reduced pressure. 
The crude product was purified using silica gel flash chromatography eluting with 95% 
EtOAc/hexanes to give product 11 (2.10 g, 8.7 mmol, 95%) as a yellow oil. Rf (20% 
EtOAc/hexanes) = 0.55; [α]21  D  = -106 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3034, 2909, 1612, 
1512, 1365, 1245, 1155, 1075, 1045, 879, 818; 1H NMR (600 MHz, CDCl3) δ 7.30 (d, J = 7.8, 
2H), 6.88 (d, J = 7.8, 2H), 5.67 (dddd, J = 9.6, 2.4, 1.2, 1.2, 1H), 5.58 (dddd, J = 9.6, 5.4, 2.4, 2.4, 
1H), 4.86 (d, J = 11.4, 1H), 4.72 (dd, J = 8.4, 3.0, 1H), 4.55 (d, J = 11.4, 1H), 4.33 (m, 1H), 3.78 
(s, 3H), 2.22 (m, 1H), 2.13 (m, 1H), 1.32 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) δ 159.0, 
130.8, 129.8, 129.4, 122.3, 113.6, 97.3, 70.4, 69.2, 55.0, 30.8, 21.0; CIHRMS Calcd for 
[C14H18O3Na]+:  257.1154.  Found 257.1148. 
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(2R,3S,4S,6R)-6-(4-methoxybenzyloxy)-2-methyl-tetrahydron-2H-pyran-3,4-diol (12): 
OPMBO
Me
HO
OH  
To a t-butanol, acetone (4.3 mL each, 1:1) solution of pyran 11 (1 g, 4.3 mmol) at 0 °C was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (4.3 mL).  Crystalline 
OsO4 (1.1 mg, 1 mol %) was added and the reaction was stirred for 12 h.  The reaction was 
quenched by adding EtOAc and satd. aq. NaHCO3. The organic layer was separated and 
concentrated. The crude product was purified by silica gel flash chromatography eluting with 
50% EtOAc/hexanes to give diol 12 (0.97 g, 3.6 mmol, 85%) as a colorless oil. Rf (50% 
EtOAc/hexanes) = 0.20; [α]21  D = -53.9 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3411, 2933, 1612, 
1513, 1245, 1161, 1032, 997, 819; 1H NMR (600 MHz, CDCl3) δ 7.23 (d, J = 8.4, 2H), 6.83 (d, J 
= 8.4, 2H), 4.84 (dd, J = 9.6, 1.8, 1H), 4.77 (d, J = 11.4, 1H), 4.45 (d, J = 11.4, 1H), 3.98 (d, J = 
3.0, 1H), 3.75 (s, 3H), 3.68 (dq, J = 9.0, 6.0, 1H), 3.22 (dd, J = 3.6, 1H), 3.05 (s, 1H), 2.98 (s, 
1H), 2.02 (ddd, J = 15, 2.4, 2.4, 1H), 1.69 (ddd, J = 14, 11.4, 3.0, 1H), 1.28 (d, J = 6.6, 3H); 13C 
NMR (150 MHz, CDCl3) δ 159.1, 129.6, 129.5, 113.7, 96.6, 72.8, 70.1, 69.4, 67.7, 55.1, 37.5, 
18.0; CIHRMS Calcd for [C14H20O5Na]+: 291.1208, Found 291.1205. 
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(2R,3R,4R,6R)-6-(4-methoxybenzyloxy)-tetrahydro-3-hydroxy-2-methyl-2H-pyran-4-yl 4-
nitrobenzoate (13): 
OPMBO
Me
HO
O
PNBz  
A THF (16 mL) solution of diol 12 (920 mg, 3.43 mmol) at 0 °C was added PPh3 (1.16 g, 5.15 
mmol) and p-nitrobenzoic acid (1.15 g, 6.87 mmol), DIAD (1.11 g, 5.49 mmol) was added 
dropwise and the reaction mixture was warmed up to room temperature and stirred for three days. 
The reaction mixture was diluted with 50 mL EtOAc, quenched with 40 mL of satd. aq. NaHCO3, 
extracted (3 x 50 mL) with ether, dried over Na2SO4, and concentrated under reduced pressure. 
The crude product was purified using silica gel flash chromatography eluting with 15% 
EtOAc/Hexanes to give nitrobenzoate 13 (1.00 g, 2.4 mmol, 70%) as a yellow solid. Rf (30% 
EtOAc/hexanes) = 0.40; mp: 38-40 °C; [α]21  D  = -40.4 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3477, 
2939, 1722, 1609, 1513, 1347, 1269, 1166, 1100, 987; 1H NMR (600 MHz, CDCl3) δ 8.15 (d, J 
= 9.0, 2H), 8.10 (d, J = 9.0, 2H), 7.21 (d, J = 8.4, 2H), 6.82 (d, J = 8.4, 2H), 5.02 (ddd, J = 11.4, 
8.4, 4.8, 1H), 4.78 (d, J = 11.4, 1H), 4.61 (dd, J = 10.2, 2.4, 1H), 4.51 (d, J = 11.4, 1H), 3.74 (s, 
3H), 3.36 (dq, J = 9.0, 6.0, 1H), 3.41 (dd, J = 9.0, 9.0, 1H), 2.93 (s, 1H), 2.35 (ddd, J = 12.6, 5.4, 
1.8, 1H), 1.78 (ddd, J = 12, 12, 9.6, 1H), 1.19 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) δ 
164.5 (2C), 159.1 (2C), 150.4 (2C), 135.0 (2C), 130.6, 129.4, 129.1, 123.3, 113.7, 97.3, 75.4, 
74.5, 71.8, 70.0, 55.0, 36.3, 17.7; CIHRMS Calcd for [C21H23NO8Na]+: 440.1321, Found 
440.1317. 
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(2R,3R,4R,6R)-3-((2R,6S)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yloxy)-6-(4-
methoxybenzyloxy)-tetrahydro-2-methyl-2H-pyran-4-yl 4-nitrobenzoate (14): 
OPMBO
H3C
O
O
O
O
PNBzH3C
 
A CH2Cl2 (1.0 mL) solution of Boc pyranone 5(α-L) (2.62 g, 11.5 mmol) and alcohol 13 (960 
mg, 2.3 mmol) was cooled to 0 °C. Pd2(DBA)3•CHCl3 (60 mg, 2.5 mol%) and PPh3 (52 mg, 10 
mol%) was added to the reaction mixture at 0 °C.  The reaction mixture was stirred at room 
temperature for 8 h.  The reaction mixture was quenched with 10 mL of satd. aq. NaHCO3, 
extracted (3 x 10 mL) with Et2O, dried over Na2SO4 and concentrated under reduced pressure.  
The crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/hexanes to give pyranone 14 (1.18 g, 2.24 mmol, 98%) as a yellow solid: Rf (30% 
EtOAc/hexanes) = 0.40; mp: 52-54 oC; [α]21  D  = -87.4 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 
2937, 1723, 1697, 1609, 1527, 1514, 1272, 1101, 979, 832; 1H NMR (600 MHz, CDCl3) δ 8.26 
(d, J = 8.4, 2H), 8.18 (d, J = 8.4, 2H), 7.24 (d, J = 8.4, 2H), 6.85 (d, J = 8.4, 2H), 6.75 (dd, J = 
10.2, 3.6, 1H), 5.97 (d, J = 10.2, 1H), 5.30 (d, J = 3.6, 1H), 5.26 (ddd, J = 11.4, 9.0, 6.0 1H), 4.81 
(d, J = 11.4, 1H), 4.66 (d, J = 9.6, 1H), 4.53 (d, J = 11.4, 1H), 4.29 (q, J = 6.6, 1H), 3.77 (s, 3H), 
3.62 (dd, J = 9.0, 9.0, 1H), 3.47 (dq, J = 9.0, 6.6, 1H), 2.38 (dd, J = 12.6, 5.4, 1H), 1.80 (ddd, J = 
12.6, 12, 12, 1H), 1.41 (d, J = 6.6, 3H), 0.88 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) δ 
196.3, 163.9, 159.4, 150.6, 142.5, 135.4, 130.7, 129.6, 129.1, 126.8, 123.5, 113.9, 97.3, 94.4, 
82.6, 73.2, 71.0, 71.0, 70.2, 55.2, 36.7, 18.3, 15.0; CIHRMS Calcd for [C27H29NO10Na]+: 
550.1689, Found 550.1690. 
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(2R,3R,4R,6R)-3-((2R, 5R, 6S)-5,6-dihydro-5-hydroxy-6-methyl-2H-pyran-2-yloxy)-6-(4-
methoxybenzyloxy)-tetrahydro-2-methyl-2H-pyran-4-yl 4-nitrobenzoate (15): 
OPMBO
H3C
O
O
HO
O
PNBz
H3C
 
Pyranone 14 (1.14 g, 2.2 mmol) was dissolved in 5.38 mL CH2Cl2, resulting solution was cooled 
to -78 °C, 5.38 mL of 0.4 M CeCl3 in methanol solution was added dropwise, followed by the 
addition of 123 mg of NaBH4. By TLC tracking, the reaction was completed after 1.5 h. The 
reaction mixture was diluted with 10 mL diethyl ether, and quenched with 2 mL water. 
Extraction by 3 x 50 mL diethyl ether, dried over Na2SO4 and concentrated under reduced 
pressure to give allylic alcohol 15 (1.11 g, 2.10 mmol, 97%) as a white solid. Rf (30% 
EtOAc/hexanes) = 0.20; mp: 159.5-160.5 °C; [α]21  D  = -114.8 (c = 1.0, CH2Cl2); IR (thin film,  
cm-1) 3384, 1718, 1527, 1513, 1282, 1104, 996, 717; 1H NMR (600 MHz, CDCl3) δ 8.26 (d, J = 
11.0, 2H), 8.19 (d, J = 11.0, 2H), 7.25 (d, J = 9.0, 2H), 6.86 (d, J = 9.0, 2H), 5.84 (d, J = 10.2, 
1H), 5.66 (ddd, J = 10.2, 2.4, 2.4, 1H), 5.21 (ddd, J = 12.0, 8.4, 5.4, 1H), 5.04 (d, J = 2.4, 1H), 
4.81 (d, J = 11.4, 1H), 4.62 (dd, J = 9.6, 2.4, 1H), 4.53 (d, J = 11.4, 1H), 3.79 (s, 3H), 3.60 (ddd, 
J = 9.0, 9.0, 1.8, 1H), 3.53 (dd, J = 9.0, 9.0, 1H), 3.46 (dq, J = 9.0, 6.0, 1H), 3.42 (dq, J = 9.0, 6.0, 
1H), 2.36 (ddd, J = 12.6, 5.4, 1.8, 1H), 1.80 (ddd, J = 12.6, 12, 10.2, 1H), 1.60 (s, 1H), 1.41 (d, J 
= 6.6, 3H), 0.81 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) δ 164.0, 159.4, 150.5, 135.8, 
133.2, 130.8, 129.7, 129.2, 126.2, 123.5, 113.9, 97.4, 95.5, 81.8, 73.4, 71.3, 70.2, 69.1, 68.6, 55.3, 
36.7, 18.4, 17.6; CIHRMS Calcd for [C27H31NO10Na]+: 552.1846, Found 552.1841. 
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(2R,3R,4R,6R)-3-((2R, 5R, 6S)-5,6-dihydro-5-(4-nitrobenzoate)-6-methyl-2H-pyran-2-
yloxy)-6-(4-methoxybenzyloxy)-tetrahydro-2-methyl-2H-pyran-4-yl 4-nitrobenzoate (16): 
OPMBO
H3C
O
O
PNBzO
O
PNBzH3C
 
A THF (0.7 mL) solution of alcohol 15 (106 mg, 0.2 mmol) at 0 °C was added PPh3 (90.4 mg, 
0.4 mmol) and p-nitrobenzoic acid (66.8 mg, 0.4 mmol), DIAD (80.9 mg, 0.4 mmol) was added 
dropwise and the reaction mixture was warmed up to room temperature and stirred for three days. 
The reaction mixture was diluted with 5 mL EtOAc, quenched with 1 mL of satd. aq. NaHCO3, 
extracted (3x10 mL) with methylene chloride, dried over Na2SO4, and concentrated under 
reduced pressure. The crude product was purified using silica gel flash chromatography eluting 
with 20% EtOAc/Hexanes to give product 16 (101 mg, 0.15 mmol, 74%) as a light yellow solid. 
Rf (30% EtOAc/hexanes) = 0.40; mp: 174-175 °C; [α]21  D = 88.2 (c = 1.0, CH2Cl2); IR (thin film, 
cm-1) 2930, 1723, 1609, 1519, 1342, 1266, 1069, 1040, 987, 834, 754; 1H NMR (600 MHz, 
CDCl3) δ 8.22 (d, J = 9, 2H), 8.17 (d, J = 9, 2H), 8.16 (d, J = 9, 2H), 8.02 (d, J = 9, 2H), 7.20 (d, 
J = 9.0, 2H), 6.81 (d, J = 9.0, 2H), 6.06 (dd, J = 10.2, 5.4, 1H), 5.96 (dd, J = 10.2, 3.0, 1H), 5.21 
(ddd, J = 12.0, 9.0, 5.4 1H), 5.15 (d, J = 3, 1H), 4.91 (dd J = 9.6, 2.4, 1H), 4.76 (d, J = 11.4, 1H), 
4.58 (dd J = 9.6, 1.8, 1H), 4.49 (d, J = 11.4, 1H), 4.03 (dq, J = 6.6, 3, 1H), 4.03 (dq, J = 9.0, 6.2, 
1H), 3.74 (s, 3H), 3.55 (dd, J = 8.4, 8.4, 1H), 2.32 (ddd, J = 12, 6.0, 1.8, 1H), 1.79 (ddd, J = 15, 
9.6, 9.6, 1H), 1.38 (d, J = 6.6, 3H), 0.71 (d, J = 6.6, 3H); 13C (150 MHz, CDCl3) 164.1, 164.0, 
159.5, 150.7, 150.6, 135.7, 135.0, 130.9, 130.7, 130.6, 129.7, 129.2, 125.1, 123.5, 123.5, 113.9, 
74 
 
97.3, 95.3, 81.8, 73.2, 71.3, 70.2, 66.1, 65.3, 55.3, 36.7, 18.5, 15.8; CIHRMS Calcd for 
[C34H34N2O13Na]+: 701.1959, Found 701.1961. 
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(2S, 3S, 6S)-6-((2R,3R,4R,6R)-6-(4-methoxybenzyloxy)-4-hydroxy-2-methyl-tetrahydro-2H-
pyran-3-yloxy)-2-methyl-3,6-dihydro-2H-pyran-3-ol (17): 
OPMBO
H3C
O
O
OH
O
HH3C
 
Bis-nitrobenzoate 16 (723 mg, 1.07 mmol) was dissolved in a mixed solvent of THF/H2O (15 
mL/3 mL) at room temperature, LiOH (102 mg, 4.28 mmol) was added and the reaction was 
stirred for 24 h. The reaction was quenched by adding 5 mL of satd. aq. NaHCO3, extracted (3 x 
50 mL) with methylene chloride, dried over Na2SO4, and concentrated under reduced pressure. 
The crude product was purified using silica gel flash chromatography eluting with 30% 
EtOAc/hexanes to give product 17 (324 mg, 0.85 mmol, 80%) as a white solid. Rf (50% 
EtOAc/hexanes) = 0.15; mp: 118-119 °C; [α]21  D = 14.0 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 
3420, 3390, 2922, 1611, 1513, 1456, 1360, 1246, 1094, 1000, 897, 823; 1H NMR (600 MHz, 
CDCl3) δ 7.27 (d, J = 8.4, 2H), 6.87 (d, J = 8.4, 2H), 6.22 (dd, J = 10.2, 5.4, 1.2, 1H), 5.87 (dd, J 
= 10.2, 3.6, 1H), 5.07 (dd, J = 2.4, 0.6, 1H), 4.82 (d, J = 12.0, 1H), 4.60 (m, 1H), 4.53 (d, J = 
12.0, 1H), 4.52 (dd, J = 9.6, 2.4, 1H), 4.22 (qd, J = 6.6, 2.4, 1H), 3.80 (s, 3H), 3.63 (m, 1H), 3.60 
(ddd, J = 12.0, 8.4, 5.4, 1H), 3.32 (dq, J = 9, 6.0, 1H), 3.04 (dd, J = 8.4, 8.4, 1H), 2.25 (ddd, J = 
12.6, 5.4, 1.8, 1H), 1.67 (ddd, J = 12.6, 12.0, 9.6, 1H), 1.51 (m, 1H), 1.35 (d, J = 6.6, 3H), 1.33 
(d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) 159.3, 130.3, 129.6, 129.5, 127.2, 113.8, 98.1, 
96.6, 88.9, 70.4, 70.1, 70.0, 67.8, 63.5, 55.3, 38.2, 18.0, 15.9; CIHRMS Calcd for [C20H28O7Na]+: 
403.1733, Found 403.1728. 
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(2S, 3S, 6S)-6-((2R,3R,4R,6R)-6-(4-methoxybenzyloxy)-4-hydroxy-2-methyl-tetrahydro-2H-
pyran-3-yloxy)-2-methyl-tetrahydro-2H-pyran-3-ol (18): 
OPMBO
H3C
O
O
OH
O
HH3C
 
Allylic alcohol 17 (415 mg, 1.09 mmol) was dissolved in CH2Cl2 (11 mL) at room temperature, 
then NBSH (1.33 g, 6.55 mmol) and Et3N (0.88 g, 8.74 mmol) were added while stirring.  The 
reaction was tracked by TLC, after 12 h, the reaction was quenched by adding 10 mL of satd. aq. 
NaHCO3, extracted (3 x 50 mL) with methylene chloride, dried over Na2SO4, and concentrated 
under reduced pressure. The crude product was purified using silica gel flash chromatography 
eluting with 30% EtOAc/hexanes to give diol 18 (420 mg, 1.09 mmol, 80%) as a yellow oil. Rf 
(50% EtOAc/hexanes) = 0.15; [α]21  D  = -98.2 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3390, 2933, 
1612, 1514, 1443, 1368, 1246, 1166, 1114, 1066, 1011, 940, 818; 1H NMR (600 MHz, CDCl3) δ 
7.27 (d, J = 9.0, 2H), 6.87 (d, J = 9.0, 2H), 4.92 (d, J = 3, 1H), 4.91 (d, J = 3, 1H), 4.81 (d, J = 
11.4, 1H), 4.79 (d, J = 1.2, 1H), 4.52 (d, J = 11.4, 1H), 4.50 (dd, J = 10.2, 2.4, 1H), 3.79 (s, 3H), 
4.14 (qd, J = 6.6, 1.2, 1H), 3.62 (m, 1H), 3.56 (m, 1H), 3.31 (dq, J = 9, 6.0, 1H), 2.98 (dd, J = 8.4, 
8.4, 1H), 2.21 (ddd, J = 12.6, 5.4, 1.8, 1H), 2.06 (ddd, J = 13.8, 13.8, 3.6, 3.6, 1H), 1.98 (ddd, J = 
13.8, 13.8, 3, 3, 1H), 1.76 (ddd, J = 13.2, 7.2, 3.6, 1H), 1.68-1.58 (m, 2H), 1.32 (d, J = 6.6, 3H), 
1.21 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) 159.3, 129.7, 129.5, 113.8, 99.6, 98.0, 88.7, 
70.4, 70.3, 69.9, 68.0, 67.1, 55.3, 38.2, 25.4, 24.2, 18.1, 16.9; CIHRMS Calcd for [C20H30O7Na]+: 
405.1889, Found 405.1885. 
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(2S,6R)-6-((2S,3S,6S)-6-((2R,3S,4R,6R)-6-(4-methoxybenzyloxy)-4-hydroxy-2-methyl-
tetrahydro-2H-pyran-3-yloxy)-2-methyl-tetrahydro-2H-pyran-3-yloxy)-2-methyl-2H-
3(6H)-one (19): 
OPMBO
H3C
O
O
O
O
H
OH3C
O
H3C
 
A CH2Cl2 (0.1 mL) solution of Boc pyranone 5(α-L) (32.23 mg, 0.14 mmol) and alcohol 18 (18 
mg, 0.047 mmol) was cooled to 0 °C. Pd2(DBA)3•CHCl3 (1.22 mg, 2.5 mol%) and PPh3 (1.06 
mg, 10 mol%) was added to the reaction mixture at 0 °C.  The reaction mixture was stirred at 
room temperature for 12 h.  The reaction mixture was quenched with 1 mL of satd. aq. NaHCO3, 
extracted (3 x 5 mL) with CH2Cl2, dried over Na2SO4 and concentrated under reduced pressure.  
The crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/Hexanes to give pyranone 19 (8 mg, 0.016 mmol, 35%) as a white solid along with 61% 
of recovered starting material 18 (11 mg, 0.029 mmol): Rf (50% EtOAc/hexanes) = 0.50; mp: 
112-113 °C; [α]21  D = -16.7 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3417, 2920, 1698, 1612, 1514, 
1457, 1371, 1247, 1067, 1030, 810; 1H NMR (600 MHz, CDCl3) δ 7.21 (d, J = 9.0, 2H), 6.82 (d, 
J = 9.0, 2H), 6.79 (dd, J = 10.2, 3.6, 1H), 6.03 (d, J = 10.2, 1H), 5.16 (d, J = 3.6, 1H), 4.87 (m 
1H), 4.75 (d, J = 11.4, 1H), 4.48 (q, J = 6.6, 1H), 4.46 (d, J = 11.4, 1H), 3.73 (s, 3H), 4.68 (m, 
1H), 4.45 (dd, J = 10, 5, 1H), 4.09 (qd, J = 6.6, 1.2, 1H), 3.60 (m, 1H), 3.50 (m, 1H), 3.25 (dq, J 
= 9, 6.0, 1H), 2.91 (dd, J = 9, 9, 1H), 2.15 (ddd, J = 12.6, 5.4, 1.8, 1H), 2.02-1.95 (m, 2H), 1.90-
1.85 (m, 1H), 1.60-1.54 (m, 2H), 1.35 (d, J = 6.6, 3H), 1.30 (d, J = 6.6, 3H), 1.16 (d, J = 6.6, 3H); 
78 
 
13C NMR (150 MHz, CDCl3) 196.5, 159.3, 142.7, 129.6, 129.5, 127.4, 113.8, 98.3, 98.0, 95.2, 
88.6, 76.1, 70.6, 70.4, 70.3, 69.9, 67.7, 55.2, 38.2, 25.1, 24.3, 18.1, 16.9, 15.1; CIHRMS Calcd 
for [C26H36O9Na]+: 515.2257, Found 515.2253. 
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(2R,3S,4R,6R)-6-(4-methoxybenzyloxy)-2-methyl-3-((2S,5S,6S)-6-methyl-5-((2R,6S)-6-
methyl-5-oxo-5,6-dihydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-
2H-pyran-4-yl acetate (20): 
OO
O
O
O
O
O
O
OO
 
Alcohol 19 (75 mg, 0.152 mmol) was dissolved in CH2Cl2 (0.2 mL) at room temperature, then 
acetic anhydride (46.7 mg, 0.457 mmol), pyridine (42.1 mg, 0.532 mmol) and a catalytic amount 
of DMAP were added in above order. The reaction mixture was stirred at room temperature for 
12 h. Reaction mixture was washed with 1 mL 1M HCl solution, followed by washing with 2 mL 
of satd. aq. NaHCO3, extracted (3 x 5 mL) with CH2Cl2, dried over Na2SO4 and concentrated 
under reduced pressure.  The crude product was purified using silica gel flash chromatography 
eluting with 20% EtOAc/hexanes to give 20 (67 mg, 0.13 mmol, 82%) as a yellow oil: Rf (50% 
EtOAc/hexanes) = 0.60; [α]21  D = -47.7 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 2928, 1733, 1699, 
1613, 1514, 1363, 1239, 1122, 1068, 1030, 962, 734; 1H NMR (600 MHz, CDCl3) δ 7.25 (d, J = 
8.3, 2H), 6.87 (d, J = 8.3, 2H), 6.86 (dd, J = 10.1, 3.5, 1H), 6.09 (d, J = 10.2, 1H), 5.22 (d, J = 
3.4, 1H), 4.95 (d, J = 2.1, 1H), 4.88 (ddd, J = 9.0, 8.0, 2, 1H), 4.80 (d, J = 11.6, 1H), 4.54 (dd, J 
= 9.7, 5.4, 1H), 4.52 (d, J = 11.6, 1H), 4.13 (q, J = 7.1, 1H), 4.00 (qd, J = 6.6, 1.2, 1H), 3.81 (s, 
3H), 3.58 (ddd, J = 3.5, 3.0, 1.6, 1H), 3.36 (dd, J = 8.0, 7.0, 1H), 3.36 (dq, J = 7, 6.6, 1H), 2.27 
(ddd, J = 12.5, 5.4, 2.0, 1H), 2.01 (ddd, J = 13.0, 3.5, 2.9, 0.7, 1H), 2.01 (s, 3H), 1.96 (ddd, J = 
80 
 
13.1, 3.5, 3.3, 0.7, 1H), 1.89 (ddd, J = 13.1, 3.8, 3.5, 3.0, 1H), 1.63 (ddd, J = 12.5, 9.7, 9, 1H), 
1.55 (ddd, J = 13.0, 3.8, 3.3, 1.2, 1H), 1.37 (d, J = 6.8, 3H), 1.35 (d, J = 6.6, 3H), 1.16 (d, J = 6.6, 
3H); 13C NMR (150 MHz, CDCl3) 196.7, 170.5, 159.4, 143.0, 129.6, 129.3, 127.3, 113.8, 98.2, 
97.4, 95.3, 80.5, 76.6, 72.2, 71.5, 70.5, 70.1, 66.6, 55.3, 36.7, 24.8, 24.2, 21.3, 18.4, 17.1, 15.1; 
CIHRMS Calcd for [C28H38O10Na]+: 557.2363, Found 557.2358. 
81 
 
(2R,3S,4R,6R)-6-(hydroxy)-2-methyl-3-((2S,5S,6S)-6-methyl-5-((2R,6S)-6-methyl-5-oxo-5,6-
dihydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-4-yl 
acetate (43): 
OHO
O
O
O
O
O
OO
 
PMB ether 20 (100 mg, 0.187 mmol) was dissolved in CH2Cl2 (0.2 mL) and water (0.1 mL) at 0 
°C, then excess DDQ (85 mg, 0.374 mmol) was added. The reaction mixture was stirred at 0 °C 
for 5h, at which time the reaction was filtered to remove precipitates, and washed with 2 mL of 
satd. aq. NaHCO3. Resulting solution was extracted (3 x 5 mL) with CH2Cl2, dried over Na2SO4 
and concentrated under reduced pressure.  The crude product was purified using silica gel flash 
chromatography eluting with 20% EtOAc/hexanes to give 43 (67 mg, 0.13 mmol, 82%) as a 
yellow oil: 
As an equilibrating mixture of stereo- and regio-isomers: 
Rf (30% EtOAc/hexanes) = 0.20; [α]21  D = 40.7 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 2928, 1733, 
1699, 1613, 1514, 1363, 1239, 1122, 1068, 1030, 962, 734; 1H NMR (600 MHz, CDCl3) δ 
6.87/6.86 (m, 1H), 6.09 (d, J = 10.2), 5.29 (s)/5.25 (ddd, J = 13.8, 9.0, 4.8), 5.21 (m), 4.96 
(m)/4.91 (ddd)/4.87 (d), 4.55 (m, 1H), 4.02 (m, 2H), 3.58 (m, 1H), 3.45 (m)/3.35(m), 3.16 (m), 
2.66 (m), 2.49 (m), 2.38 (ddd, J = 12.6, 5.4, 1.8), 2.25 (ddd, J = 13.2, 5.4, 1.8), 2.15-1.80 (m), 
2.06/2.05 (s, 3H), 1.73-1.4 (m), 1.4-1.16 (m); 13C NMR (150 MHz, CDCl3) 196.84/196.78, 
82 
 
170.5/170.4, 143.03/142.98, 127.3, 98.3/98.2, 95.4/95.3, 93.43/93.39, 91.39/91.37, 81.0, 
80.2,72.0/ 71.7, 70.6/70.2, 67.3/66.6, 38.1/35.6, 29.8, 24.8, 24.3, 21.4/21.3, 18.4, 17.2, 15.1; 
CIHRMS Calcd for [C20H30NaO9]+: 437.8, Found 437.1786. 
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(2S,6S)-6-(4-methoxybenzyloxy)-2-methyl-2H-pyran-3(6H)-one (ent-9):†† 
O CH3PMBO
O
 
A CH2Cl2 (10 mL) solution of tert-butyl (2S,6R)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yl 
carbonate 6(β-D) (11.4 g, 50 mmol) and 4-methoxybenzyl alcohol (13.8 g, 100 mL) was cooled 
to 0 °C, Pd2(DBA)3•CHCl3 (260 mg, 1.0 mol%) and PPh3 (226 mg, 2 mol%) were added to the 
reaction mixture at 0 °C. The reaction mixture was stirred at 0 °C for 2 h, and was quenched by 
adding 50 mL of satd. aq. NaHCO3. Resulting solution was extracted three times with ether, 
dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
using silica gel flash chromatography eluting with 5% EtOAc/hexanes to give pyranone ent-9  
(12.1 g, 50 mmol, 99%) as a yellow oil:  Rf (10% EtOAc/hexanes) = 0.15; [α]21  D = 22.9 (c = 1.0, 
CH2Cl2); IR (thin film, cm-1) 2938, 2837, 1696, 1513, 1246, 1054, 1008, 818, 802; 1H NMR (600 
MHz, CDCl3) δ 7.23 (d, J = 8.4, 2H), 6.88 (d, J = 8.4, 2H), 6.83 (dd, J = 10.2, 1.2, 1H), 6.03 (d, J 
= 10.2, 1H), 5.29 (d, J = 1.2, 1H), 4.79 (d, J = 11.4, 1H), 4.54 (d, J = 11.4, 1H), 4.15 (q, J = 6.6, 
1H), 3.71 (s, 3H), 1.45 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) δ 196.5, 159.2, 146.5, 
129.5, 128.7, 127.7, 113.6, 93.9, 74.9, 69.5, 54.9, 16.9; CIHRMS Calcd for [C14H16O4H]+: 
249.1127.  Found 249.1122. 
 
 
 
                                                
†† For compounds in the enantiomeric series only 1H NMR, 13C NMR and optical rotations were recorded. 
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(2S,6S)-6-(4-methoxybenzyloxy)-3,6-dihydro-2-methyl-2H-pyran-3-ol (ent-10a/b):†† 
O CH3PMBO
OH
 
Pyranone 9 (12 g, 50 mmol) was dissolved in 100 mL CH2Cl2, and resulting solution was cooled 
to -78 °C. 100 mL of 0.4 M CeCl3 in methanol solution was added in a dropwise fashion, 
followed by adding 1 g of NaBH4. By TLC tracking, the reaction was done after 1.5 h. The 
reaction mixture was diluted with 10 mL diethyl ether, and quenched with 10 mL water. 
Resulting solution was extracted with 3 x 20 mL diethyl ether, dried over anhydrous sodium 
sulfate, and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography eluting with 80% EtOAc/Hexane to give allylic alcohol ent-10a/b as a 
mixture of diastereomers (12.0 g, 49 mmol, 99%) as a colorless oil: Rf (30% EtOAc/hexanes) = 
0.45; [α]21  D = 59 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3421, 2977, 2871, 1612, 1513, 1244, 
1172, 1031, 818, 788;  
10a 1H NMR (600 MHz, CDCl3) δ 7.26 (d, J = 8.4, 2H), 6.85 (d, J = 8.4, 2H), 6.11 (ddd, J = 
10.2, 5.4, 1.8, 1H), 5.81 (d, J = 10.2, 1H), 5.09 (m, 1H), 4.80 (d, J = 11.4, 1H), 4.56 (d, J = 11.4, 
1H), 3.77 (s, 3H), 3.68 (m, 1H), 3.64 (m, 1H), 2.00 (m, 1H), 1.30 (d, J = 6, 3H); 10b 1H NMR 
(600 MHz, CDCl3) δ 7.26 (d, J = 8.4, 2H), 6.85 (d, J = 8.4, 2H), 5.92 (d, J = 10.2, 1H), 5.75 (d, J 
= 10.2, 1H), 5.09 (m, 1H), 4.76 (d, J = 11.4, 1H), 4.52 (d, J = 11.4, 1H), 3.77 (s, 3H), 3.71 (m, 
1H), 3.68 (m, 1H), 2.00 (m, 1H), 1.35 (d, J = 6, 3H); 13C NMR (150 MHz, CDCl3) major isomer 
δ 159.3 (2C), 131.2 (2C), 129.7, 129.6, 113.8, 96.7, 71.5, 69.6, 68.4, 64.8, 55.3, 16.6; CIHRMS 
Calcd for [C14H18O4Na]+:  273.1103.  Found 273.1100. 
85 
 
(2S,6S)-2-(4-methoxybenzyloxy)-3,6-dihydro-6-methyl-2H-pyran (ent-11):†† 
O CH3PMBO  
A flask charged with dry N-Methyl morpholine (NMM) 80 mL, triphenyl phosphine (27.5 g, 120 
mmol) was cooled to -30 °C under argon atmosphere. Diethylazodicarboxylate (20 mL, 150 
mmol) was added and the reaction was stirred for 5 min, allylic alcohol (10 g, 41 mmol) was 
added in a solution of 1 M NMM (50 mL), the resulting reaction mixture was stirred for 10 min, 
followed by addition of o-nitrobenzenesulfonyl hydrazide (NBSH) (30 g). The reaction was 
stirred at -30 °C for 2 h and monitored by TLC.  Upon consumption of 10a/b, the reaction was 
warmed to room temperature and stirred for another 2 h. The reaction mixture was diluted with 
ether (100 mL) and was quenched with 50 mL of satd. aq. NaHCO3, extracted (3 x 50 mL) with 
ether, dried over Na2SO4, and concentrated under reduced pressure. The crude product was 
purified using silica gel flash chromatography eluting with 95% EtOAc/hexanes to give ent-11 
product (9.10 g, 40 mmol, 98%) as a yellow oil. Rf (20% EtOAc/hexanes) = 0.55; [α]21  D  = 107 (c 
= 1.0, CH2Cl2); IR (thin film, cm-1) 3034, 2909, 1612, 1512, 1365, 1245, 1155, 1075, 1045, 879, 
818; 1H NMR (600 MHz, CDCl3) δ 7.30 (d, J = 7.8, 2H), 6.88 (d, J = 7.8, 2H), 5.67 (dddd, J = 
9.6, 2.4, 1.2, 1.2, 1H), 5.58 (dddd, J = 9.6, 5.4, 2.4, 2.4, 1H), 4.86 (d, J = 11.4, 1H), 4.72 (dd, J = 
8.4, 3.0, 1H), 4.55 (d, J = 11.4, 1H), 4.33 (m, 1H), 3.78 (s, 3H), 2.22 (m, 1H), 2.13 (m, 1H), 1.32 
(d, J = 7.2, 3H); 13C NMR (150 MHz, CDCl3) δ 159.0, 130.8, 129.8, 129.4, 122.3, 113.6, 97.3, 
70.4, 69.2, 55.0, 30.8, 21.0; CIHRMS Calcd for [C14H18O3Na]+:  257.1154.  Found 257.1148. 
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(2S,3R,4R,6S)-6-(4-methoxybenzyloxy)-2-methyl-tetrahydron-2H-pyran-3,4-diol (ent-12):†† 
O
OHHO
Me
OPMB  
To a t-butanol/acetone (25 mL each, 1:1) solution of pyran ent-11 (5 g, 22 mmol) at 0 °C was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (25 mL).  Crystalline 
OsO4 (5 mg, 5 mol %) was added and the reaction was stirred for 12 h.  The reaction was 
quenched by adding EtOAc and satd. aq. NaHCO3. The organic layer was separated and 
concentrated. The crude product was purified using silica gel flash chromatography eluting with 
50% EtOAc/hexanes to give diol ent-12 (5.1 g, 19 mmol, 86%) as a colorless oil. Rf (50% 
EtOAc/hexanes) = 0.20; [α]21  D  = 53.5 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3411, 2933, 1612, 
1513, 1245, 1161, 1032, 997, 819; 1H NMR (600 MHz, CDCl3) δ 7.23 (d, J = 8.4, 2H), 6.83 (d, J 
= 8.4, 2H), 4.84 (dd, J = 9.6, 1.8, 1H), 4.77 (d, J = 11.4, 1H), 4.45 (d, J = 11.4, 1H), 3.98 (d, J = 
3.0, 1H), 3.75 (s, 3H), 3.68 (dq, J = 9.0, 6.0, 1H), 3.22 (dd, J = 3.6, 1H), 3.05 (s, 1H), 2.98 (s, 
1H), 2.02 (ddd, J = 15, 2.4, 2.4, 1H), 1.69 (ddd, J = 14, 11.4, 3.0, 1H), 1.28 (d, J = 6.6, 3H); 13C 
NMR (150 MHz, CDCl3) δ 159.1, 129.6, 129.5, 113.7, 96.6, 72.8, 70.1, 69.4, 67.7, 55.1, 37.5, 
18.0; CIHRMS Calcd for [C14H20O5Na]+: 291.1208, Found 291.1205. 
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(2S,3S,4S,6S)-6-(4-methoxybenzyloxy)-tetrahydro-3-hydroxy-2-methyl-2H-pyran-4-yl 4-
nitrobenzoate (ent-13):†† 
O
HO
PNBzO Me
OPMB  
A THF (16 mL) solution of diol ent-12 (5.0 g, 18.6 mmol) at 0 °C was added PPh3 (5.8 g, 26 
mmol), p-nitrobenzoic acid (5.8 g, 26 mmol), and DIAD (5.6 g, 28 mmol) was added dropwise. 
The reaction mixture was warmed up to room temperature and stirred for three days. The 
reaction mixture was diluted with 100 mL EtOAc, quenched with 100 mL of satd. aq. NaHCO3, 
extracted (3 x 50 mL) with ether, dried over Na2SO4, and concentrated under reduced pressure. 
The crude product was purified using silica gel flash chromatography eluting with 15% 
EtOAc/Hexanes to give nitrobenzoate ent-13 (4.98 g, 12 mmol, 65%) as a yellow solid. Rf (30% 
EtOAc/hexanes) = 0.40; mp: 38-40 °C; [α]21  D = 40.0 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3477, 
2939, 1722, 1609, 1513, 1347, 1269, 1166, 1100, 987; 1H NMR (600 MHz, CDCl3) δ 8.15 (d, J 
= 9.0, 2H), 8.10 (d, J = 9.0, 2H), 7.21 (d, J = 8.4, 2H), 6.82 (d, J = 8.4, 2H), 5.02 (ddd, J = 11.4, 
8.4, 4.8, 1H), 4.78 (d, J = 11.4, 1H), 4.61 (dd, J = 10.2, 2.4, 1H), 4.51 (d, J = 11.4, 1H), 3.74 (s, 
3H), 3.36 (dq, J = 9.0, 6.0, 1H), 3.41 (dd, J = 9.0, 9.0, 1H), 2.93 (s, 1H), 2.35 (ddd, J = 12.6, 5.4, 
1.8, 1H), 1.78 (ddd, J = 12, 12, 9.6, 1H), 1.19 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) δ 
164.5 (2C), 159.1 (2C), 150.4 (2C), 135.0 (2C), 130.6, 129.4, 129.1, 123.3, 113.7, 97.3, 75.4, 
74.5, 71.8, 70.0, 55.0, 36.3, 17.7; CIHRMS Calcd for [C21H23NO8Na]+: 440.1321, Found 
440.1317. 
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(2S,3S,4S,6S)-3-((2R,6S)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yloxy)-6-(4-
methoxybenzyloxy)-tetrahydro-2-methyl-2H-pyran-4-yl 4-nitrobenzoate (ent-14):†† 
O
O
PNBzO Me
OPMB
O
O
Me
 
A CH2Cl2 (1.0 mL) solution of Boc pyranone 5(α-L) (5.0 g, 22 mmol) and alcohol ent-13 (2.0 
mg, 4.8 mmol) was cooled to 0 °C. Pd2(DBA)3•CHCl3 (60 mg, 1.3 mol%) and PPh3 (52 mg, 5 
mol%) were added to the reaction mixture at 0 °C.  After 8 hours stirring, the reaction mixture 
was quenched with 20 mL of satd. aq. NaHCO3, extracted (3 x 20 mL) with Et2O, dried over 
Na2SO4 and concentrated under reduced pressure.  The crude product was purified using silica 
gel flash chromatography eluting with 20% EtOAc/hexanes to give pyranone ent-14 (2.2 g, 4.2 
mmol, 87%) as a yellow solid: Rf (30% EtOAc/hexanes) = 0.40; mp: 52-54oC; [α]21  D = 88 (c = 
1.0, CH2Cl2); IR (thin film, cm-1) 2937, 1723, 1697, 1609, 1527, 1514, 1272, 1101, 979, 832; 1H 
NMR (600 MHz, CDCl3) δ 8.26 (d, J = 8.4, 2H), 8.18 (d, J = 8.4, 2H), 7.24 (d, J = 8.4, 2H), 6.85 
(d, J = 8.4, 2H), 6.75 (dd, J = 10.2, 3.6, 1H), 5.97 (d, J = 10.2, 1H), 5.30 (d, J = 3.6, 1H), 5.26 
(ddd, J = 11.4, 9.0, 6.0 1H), 4.81 (d, J = 11.4, 1H), 4.66 (d, J = 9.6, 1H), 4.53 (d, J = 11.4, 1H), 
4.29 (q, J = 6.6, 1H), 3.77 (s, 3H), 3.62 (dd, J = 9.0, 9.0, 1H), 3.47 (dq, J = 9.0, 6.6, 1H), 2.38 
(dd, J = 12.6, 5.4, 1H), 1.80 (ddd, J = 12.6, 12, 12, 1H), 1.41 (d, J = 6.6, 3H), 0.88 (d, J = 6.6, 
3H); 13C NMR (150 MHz, CDCl3) δ 196.3, 163.9, 159.4, 150.6, 142.5, 135.4, 130.7, 129.6, 
129.1, 126.8, 123.5, 113.9, 97.3, 94.4, 82.6, 73.2, 71.0, 71.0, 70.2, 55.2, 36.7, 18.3, 15.0; 
CIHRMS Calcd for [C27H29NO10Na]+: 550.1689, Found 550.1690. 
89 
 
(2S,3S,4S,6S)-3-((2S, 5R, 6R)-5,6-dihydro-5-hydroxy-6-methyl-2H-pyran-2-yloxy)-6-(4-
methoxybenzyloxy)-tetrahydro-2-methyl-2H-pyran-4-yl 4-nitrobenzoate (ent-15):†† 
O
O
PNBzO Me
OPMB
O OHMe
 
Pyranone ent-14 (2.0 g, 3.9 mmol) was dissolved in 10 mL CH2Cl2, resulting solution was 
cooled to -78 °C, 10 mL of 0.4 M CeCl3 in methanol solution was added dropwise, followed by 
200 mg of NaBH4. By TLC tracking, the reaction was completed after 1.5 h. The reaction 
mixture was diluted with 50 mL diethyl ether, and quenched with 2 mL water. Extraction by 3 x 
50 mL diethyl ether, drying over Na2SO4 and concentration under reduced pressure gave allylic 
alcohol ent-15 (2.0 g, 3.8 mmol, 97%) as a white solid. Rf (30% EtOAc/hexanes) = 0.20; mp: 
159.5-160.5 °C; [α]21  D  = 114 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3384, 1718, 1527, 1513, 
1282, 1104, 996, 717; 1H NMR (150 MHz, CDCl3) δ 8.26 (d, J = 11, 1H), 8.19 (d, J = 11, 1H), 
7.25 (d, J = 9.0, 2H), 6.86 (d, J = 9.0, 2H), 5.84 (d, J = 10.2, 1H), 5.66 (ddd, J = 10.2, 2.4, 2.4, 
1H), 5.21 (ddd, J = 12.0, 8.4, 5.4 1H), 5.04 (d, J = 2.4, 1H), 4.81 (d, J = 11.4, 1H), 4.62 (dd, J = 
9.6, 2.4, 1H), 4.53 (d, J = 11.4, 1H), 3.79 (s, 3H), 3.60 (ddd, J = 9.0, 9.0, 1.8, 1H), 3.53 (dd, J = 
9.0, 9.0, 1H), 3.46 (dq, J = 9.0, 6.0, 1H), 3.42 (dq, J = 9.0, 6.0, 1H), 2.36 (ddd, J = 12.6, 5.4, 1.8, 
1H), 1.80 (ddd, J = 12.6, 12, 10.2, 1H), 1.60(s, 1H), 1.41 (d, J = 6.6, 1H), 0.81 (d, J = 6.0, 1H); 
13C NMR (150 MHz, CDCl3) δ 164.0, 159.4, 150.5, 135.8, 133.2, 130.8, 129.7, 129.2, 126.2, 
123.5, 113.9, 97.4, 95.5, 81.8, 73.4, 71.3, 70.2, 69.1, 68.6, 55.3, 36.7, 18.4, 17.6; CIHRMS Calcd 
for [C27H31NO10Na]+: 552.1846, Found 552.1841. 
90 
 
(2S,3S,4S,6S)-3-((2S, 5S, 6R)-5,6-dihydro-5-(4-nitrobenzoate)-6-methyl-2H-pyran-2-yloxy)-
6-(4-methoxybenzyloxy)-tetrahydro-2-methyl-2H-pyran-4-yl 4-nitrobenzoate (ent-16):†† 
O
O
PNBzO Me
OPMB
O
PNBzO
Me
 
A THF (0.7 mL) solution of alcohol ent-15 (1 g, 2.0 mmol) at 0 °C was added PPh3 (910 mg, 4.0 
mmol) and p-nitrobenzoic acid (670 mg, 4.0 mmol). DIAD (8.0 g, 4.0 mmol) was added 
dropwise and the reaction mixture was warmed up to room temperature and stirred for three days. 
The reaction mixture was diluted with 5 mL EtOAc, quenched with 10 mL of satd. aq. NaHCO3, 
extracted (3 x 20 mL) with methylene chloride, dried over Na2SO4, and concentrated under 
reduced pressure. The crude product was purified using silica gel flash chromatography eluting 
with 20% EtOAc/Hexanes to give ent-16 product (550 mg, 82 mmol, 41%) as a light yellow 
solid. Rf (30% EtOAc/hexanes) = 0.40; mp: 174-175 °C; [α]21  D = –89.9 (c = 1.0, CH2Cl2); IR 
(thin film, cm-1) 2930, 1723, 1609, 1519, 1342, 1266, 1069, 1040, 987, 834, 754; 1H NMR (600 
MHz, CDCl3) δ 8.22 (d, J = 9.0, 2H), 8.17 (d, J = 9.0, 2H), 8.16 (d, J = 9.0, 2H), 8.02 (d, J = 9.0, 
2H), 7.20 (d, J = 9.0, 2H), 6.81 (d, J = 9.0, 2H), 6.06 (dd, J = 10.2, 5.4, 1H), 5.96 (dd, J = 10.2, 
3.0, 1H), 5.21 (ddd, J = 12.0, 9.0, 5.4 1H), 5.15 (d, J = 3, 1H), 4.91 (dd J = 9.6, 2.4, 1H), 4.76 (d, 
J = 11.4, 1H), 4.58 (dd J = 9.6, 1.8, 1H), 4.49 (d, J = 11.4, 1H), 4.03 (dq, J = 6.6, 3, 1H), 4.03 
(dq, J = 9.0, 6.2, 1H), 3.74 (s, 3H), 3.55 (dd, J = 8.4, 8.4, 1H), 2.32 (ddd, J = 12, 6.0, 1.8, 1H), 
1.79 (ddd, J = 15, 9.6, 9.6, 1H), 1.38 (d, J = 6.6, 3H), 0.71 (d, J = 6.6, 3H); 13C (150 MHz, 
CDCl3) 164.1, 164.0, 159.5, 150.7, 150.6, 135.7, 135.0, 130.9, 130.7, 130.6, 129.7, 129.2, 125.1, 
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123.5, 123.5, 113.9, 97.3, 95.3, 81.8, 73.2, 71.3, 70.2, 66.1, 65.3, 55.3, 36.7, 18.5, 15.8; 
CIHRMS Calcd for [C34H34N2O13Na]+: 701.1959, Found 701.1961. 
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(2R, 3R, 6R)-6-((2S,3S,4S,6S)-6-(4-methoxybenzyloxy)-4-hydroxy-2-methyl-tetrahydro-2H-
pyran-3-yloxy)-2-methyl-3,6-dihydro-2H-pyran-3-ol (ent-17):†† 
O
O
HO Me
OPMB
O
OH
Me
 
Bis-nitrobenzoate ent-16 (500 mg, 0.74 mmol) was dissolved in a mixed solvent of THF/H2O 
(15 mL/3 mL) at room temperature, LiOH (100 mg, 4.20 mmol) was added and the reaction 
stirred for 24 h. The reaction was quenched by adding 5 mL of satd. aq. NaHCO3, extracted (3 x 
50 mL) with methylene chloride, dried over Na2SO4, and concentrated under reduced pressure. 
The crude product was purified using silica gel flash chromatography eluting with 30% 
EtOAc/hexanes to give product ent-17 (265 mg, 0.70 mmol, 70%) as a white solid. Rf (50% 
EtOAc/hexanes) = 0.15; mp: 118-119 °C; [α]21  D = -15.0 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 
3420, 3390, 2922, 1611, 1513, 1456, 1360, 1246, 1094, 1000, 897, 823; 1H NMR (600 MHz, 
CDCl3) δ 7.27 (d, J = 8.4, 2H), 6.87 (d, J = 8.4, 2H), 6.22 (dd, J = 10.2, 5.4, 1.2, 1H), 5.87 (dd, J 
= 10.2, 3.6, 1H), 5.07 (dd, J = 2.4, 0.6, 1H), 4.82 (d, J = 12.0, 1H), 4.60 (m, 1H), 4.53 (d, J = 
12.0, 1H), 4.52 (dd, J = 9.6, 2.4, 1H), 4.22 (qd, J = 6.6, 2.4, 1H), 3.80 (s, 3H), 3.63 (m, 1H), 3.60 
(ddd, J = 12.0, 8.4, 5.4, 1H), 3.32 (dq, J = 9, 6.0, 1H), 3.04 (dd, J = 8.4, 8.4, 1H), 2.25 (ddd, J = 
12.6, 5.4, 1.8, 1H), 1.67 (ddd, J = 12.6, 12.0, 9.6, 1H), 1.51 (m, 1H), 1.35 (d, J = 6.6, 3H), 1.33 
(d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) 159.3, 130.3, 129.6, 129.5, 127.2, 113.8, 98.1, 
96.6, 88.9, 70.4, 70.1, 70.0, 67.8, 63.5, 55.3, 38.2, 18.0, 15.9; CIHRMS Calcd for [C20H28O7Na]+: 
403.1733, Found 403.1728. 
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(2R, 3R, 6R)-6-((2S,3S,4S,6S)-6-(4-methoxybenzyloxy)-4-hydroxy-2-methyl-tetrahydro-2H-
pyran-3-yloxy)-2-methyl-tetrahydro-2H-pyran-3-ol (ent-18):†† 
O
O
HO Me
OPMB
O
OH
Me
 
Allylic alcohol ent-17 (250 mg, 66 mmol) was dissolved in CH2Cl2 (11 mL) at room temperature. 
NBSH (1.33 g, 6.55 mmol) and Et3N (0.88 g, 8.74 mmol) were added while stirring.  The 
reaction was tracked by TLC. The reaction was quenched by adding 10 mL of satd. aq. NaHCO3 
after 12 hours, extracted (3 x 50 mL) with methylene chloride, dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified using silica gel flash 
chromatography eluting with 30% EtOAc/hexanes to give diol ent-18 (250 mg, 66 mmol, 99%) 
as a yellow oil. Rf (50% EtOAc/hexanes) = 0.15; [α]21  D = 95 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 
3390, 2933, 1612, 1514, 1443, 1368, 1246, 1166, 1114, 1066, 1011, 940, 818; 1H NMR (600 
MHz, CDCl3) δ 7.27 (d, J = 9.0, 2H), 6.87 (d, J = 9.0, 2H), 4.92 (d, J = 3, 1H), 4.91 (d, J = 3, 
1H), 4.81 (d, J = 11.4, 1H), 4.79 (d, J = 1.2, 1H), 4.52 (d, J = 11.4, 1H), 4.50 (dd, J = 10.2, 2.4, 
1H), 3.79 (s, 3H), 4.14 (qd, J = 6.6, 1.2, 1H), 3.62 (m, 1H), 3.56 (m, 1H), 3.31 (dq, J = 9, 6.0, 
1H), 2.98 (dd, J = 8.4, 8.4, 1H), 2.21 (ddd, J = 12.6, 5.4, 1.8, 1H), 2.06 (ddd, J = 13.8, 13.8, 3.6, 
3.6, 1H), 1.98 (ddd, J = 13.8, 13.8, 3, 3, 1H), 1.76 (ddd, J = 13.2, 7.2, 3.6, 1H), 1.68-1.58 (m, 
2H), 1.32 (d, J = 6.6, 3H), 1.21 (d, J = 6.6, 3H); 13C NMR (150 MHz, CDCl3) 159.3, 129.7, 
129.5, 113.8, 99.6, 98.0, 88.7, 70.4, 70.3, 69.9, 68.0, 67.1, 55.3, 38.2, 25.4, 24.2, 18.1, 16.9; 
CIHRMS Calcd for [C20H30O7Na]+: 405.1889, Found 405.1885. 
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(2R,6S)-6-((2R,3R,6R)-6-((2S,3R,4S,6S)-6-(4-methoxybenzyloxy)-4-hydroxy-2-methyl-
tetrahydro-2H-pyran-3-yloxy)-2-methyl-tetrahydro-2H-pyran-3-yloxy)-2-methyl-2H-
3(6H)-pyran-3-one (ent-19):†† 
O
O
HO Me
OPMB
O
O
Me
O
O
Me
 
A CH2Cl2 (0.1 mL) solution of Boc pyranone 5(α-L) (65 mg, 29 mmol) and alcohol (50 mg, 0.13 
mmol) was cooled to 0 °C. Pd2(DBA)3•CHCl3 (1.22 mg, 1.3 mol%) and PPh3 (1.06 mg, 5 mol%) 
were added to the reaction mixture at 0 °C.  After stirring at room temperature for 12 h, the 
reaction mixture was quenched with 1 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with 
CH2Cl2, dried over Na2SO4 and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 20% EtOAc/Hexanes to give 
pyranone ent-19 (25 mg, 0.05 mmol, 40%) as a white solid along with 50% recovered starting 
material ent-18 (25 mg, 0.065 mmol): Rf (50% EtOAc/hexane) = 0.50; mp: 112-113 °C; [α]21  D = 
18 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 3417, 2920, 1698, 1612, 1514, 1457, 1371, 1247, 1067, 
1030, 810; 1H NMR (600 MHz, CDCl3) δ 7.21 (d, J = 9.0, 2H), 6.82 (d, J = 9.0, 2H), 6.79 (dd, J 
= 10.2, 3.6, 1H), 6.03 (d, J = 10.2, 1H), 5.16 (d, J = 3.6, 1H), 4.87 (m, 1H), 4.75 (d, J = 11.4, 1H), 
4.48 (q, J = 6.6, 1H), 4.46 (d, J = 11.4, 1H), 3.73 (s, 3H), 4.68 (m, 1H), 4.45 (dd, J = 10, 5, 1H), 
4.09 (qd, J = 6.6, 1.2, 1H), 3.60 (m, 1H), 3.50 (m, 1H), 3.25 (dq, J = 9, 6.0, 1H), 2.91 (dd, J = 9, 
9, 1H), 2.15 (ddd, J = 12.6, 5.4, 1.8, 1H), 2.02-1.95 (m, 2H), 1.90-1.85 (m, 1H), 1.60-1.54 (m, 
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2H), 1.35 (d, J = 6.6, 3H), 1.30 (d, J = 6.6, 3H), 1.16 (d, J = 6.6, 3H); 13C NMR (150 MHz, 
CDCl3) 196.5, 159.3, 142.7, 129.6, 129.5, 127.4, 113.8, 98.3, 98.0, 95.2, 88.6, 76.1, 70.6, 70.4, 
70.3, 69.9, 67.7, 55.2, 38.2, 25.1, 24.3, 18.1, 16.9, 15.1; CIHRMS Calcd for [C26H36O9Na]+: 
515.2257, Found 515.2253. 
 
H
O
O
CH3
O
O
O
O
OH3C
O
H3C
(2S,6R)-6-((2S,3S,6S)-6-((2R,3S,4R,6R)-6-(4-methoxybenzyloxy)-4-acetoxy-2-
methyl-tetrahydro-2H-pyran-3-yloxy)-2-methyl-tetrahydro-2H-pyran-3-yloxy)-
2-methyl-2H-3(6H)-one (20):
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
CH3H
H
H
H
H
H
3a 4.88 (ddd, J = 9.0, 8.0, 2, 1H)
3aCH3 2.01 (s, 3H)
H3C
O
The regiochemistry of glycosylation is confirmed by the 3 
bond coupling correlation between the C3 ring carbon and 
the methyl group of the C3 acetate in the HMQC spectra  
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C: Experimental Procedures for Chapter II: 
(6R)-6-pivaloyl-(2R)-2-methyl 2H-pyran-3(6H)-one (35).   
O
O
O
O
 
Compound 7a (2.22 g, 8.59 mmol), 30 mL of CH2Cl2, and 1.5 mL of Et3N were added to a round 
bottom flask and cooled to -78 °C.  A catalytic amount (53 mg, 0.43 mmol) of DMAP and 
pivaloyl chloride (1.06 mL, 8.59 mmol) were added and the solution was stirred for 3 h at -78 oC.  
The reaction was quenched with 50 mL of sat. aq. NaHCO3, extracted (3 x 50 mL) with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was purified using 
silica gel flash chromatography eluting with 10 % EtOAc/hexanes to give 2.41 g (7.04 mmol, 82 
%) of 35. Rf (20 % EtOAc/hexanes) = 0.4; [α]21D = -66 (c = 0.1, CH2Cl2); IR (thin film, cm-1) 
2935, 2910, 2855, 1738, 1692, 1461, 1399, 1279; 1H NMR (600 MHz, CDCl3) δ 6.88 (dd, J = 
10.2, 3.6 Hz, 1H), 6.46 (d, J = 3.6 Hz, 1H), 6.19 (d, J = 10.2 Hz, 1H), 4.57 (q, J = 6.6 Hz, 1H), 
1.40 (d, J = 6.6 Hz, 3H), 1.23 (s, 9H), 13C NMR (150 MHz, CDCl3) δ 195.9, 177.0, 141.8, 128.2, 
86.9, 72.3, 39.2, 27.0, 15.4; CI HRMS calcd for [C11H16O4]+: 212.1049,  Found 212.1045. 
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((2R,5S,6R)-5,6-dihydro-5-hydroxy-6-methyl-2H-pyran-2-yl pivalate (36). 
O
OH
O
O
 
A solution of pyranone 35 (580 mg, 2.74 mmol) in CH2Cl2 (1.5 mL) and 0.4 M CeCl3/MeOH 
(1.5 mL) was cooled to -78 °C. NaBH4 (58.4 mg, 1.54 mmol) was added and the reaction 
mixture was stirred for 4 h at -78 °C. The resulting solution was diluted with ether (10 mL), 
quenched with 5 mL of saturated NaHCO3, extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and 
concentrated under reduced pressure. The crude product was purified using silica gel 
chromatography eluting with 40% EtOAc/hexane to give enol 36 (400 mg, 1.90 mmol, 68%) as a 
white solid, mp: 62.5-64.0 °C; Rf = 0.30 (40% EtOAc/Hexane); [α]21  D = 21 (c = 0.55, CH2Cl2); 
IR (thin film, cm-1) 3391, 2972, 2933, 2837, 1720, 1612, 1513, 1246, 1029, 999, 819; 1H NMR 
(600 MHz, CDCl3) δ 6.21 (dd, J = 2.4, 1.8 Hz, 1H), 6.04 (d, J = 9.6 Hz, 1H), 5.75 (ddd, J = 10.2, 
2.4, 2.4 Hz, 1H), 3.90 (d, J = 8.4 Hz, 1H), 3.72 (m, 1H), 2.20 (s, 1H), 1.31 (d, J = 6.6 Hz, 3H), 
1.20 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 177.7, 134.7, 125.1, 88.4, 70.3, 69.2, 39.1, 27.1, 
18.0; CIHRMS: Calculated for [C11H18O4Na+]: 237.1102.  Found: 237.1099. 
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((2R,5S,6R)-3,4,5,6-tetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl pivalate (37). 
O
OH
O
O
 
A solution of allylic alcohol 36 (370 mg, 1.73 mmol) was dissolved in CH2Cl2 (11 mL) at room 
temperature. NBSH (1.33 g, 6.55 mmol) and Et3N (0.88 g, 8.74 mmol) were added while stirring.  
The reaction was tracked by TLC.  After 12 h, the reaction was quenched by adding 10 mL of 
satd. aq. NaHCO3, extracted (3 x 50 mL) with methylene chloride, dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified using silica gel flash 
chromatography eluting with 30% EtOAc/hexanes to give 37 (420 mg, 1.09 mmol, 80%) as a 
yellow oil. Rf (50% EtOAc/hexanes) = 0.15; [α]21  D = -105 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 
3390, 2933, 1724, 1443, 1368, 1246, 1166, 1114, 1066, 1011, 940, 818; 1H NMR; 1H NMR (600 
MHz, CDCl3) δ 6.01 (s, 1H), 6.04 (d, J = 9.6 Hz, 1H), 3.65 (dq, J = 9, 6.6, 1H), 3.30 (ddd, J = 
10.2, 5.4, 1.8, 1H), 1.98-1.65 (m, 4H), 1.23 (d, J = 6.6 Hz, 3H), 1.20 (s, 9H); 13C NMR (150 
MHz, CDCl3) δ 177.0 , 90.7, 71.8, 71.5, 39.1, 28.5, 27.2, 27.0, 17.9; CIHRMS: Calculated for 
[C11H20O4Na+]: 239.1259.  Found: 239.1264 
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((2R,5S,6R)-4-((2’S,6’R)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yloxy)-3,4,5,6-tetrahydro-
5-hydroxy-6-methyl-2H-pyran-2-yl pivalate (38). 
OO
O
O
O
O
 
A CH2Cl2 (1.0 mL) solution of Boc pyranone 5(α-L) (422 mg, 1.85 mmol) and alcohol 37 (200 
mg, 0.93 mmol) was cooled to 0 °C. Pd2(DBA)3•CHCl3 (24 mg, 2.5 mol%) and PPh3 (21 mg, 10 
mol%) were added to the reaction mixture at 0 °C.  After stirring at room temperature for 8 h, the 
reaction mixture was quenched with 10 mL of satd. aq. NaHCO3, extracted (3 x 10 mL) with 
Et2O, dried over Na2SO4 and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give 
pyranone 38 (210 mg, 0.65 mmol, 70%) as a yellow oil: Rf (30% EtOAc/hexanes) = 0.5; [α]21  D = 
-105 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 2933, 1731, 1701, 1443, 1368, 1246, 1166, 1114, 
1066, 1011, 940, 818; 1H NMR; 1H NMR (600 MHz, CDCl3) δ 6.75 (dd, J = 10.2, 3.6, 1H), 6.04 
(d, J = 10.2, 1H), 5.98 (s, 1H), 5.25 (d, J = 9.6 Hz, 1H), 4.55 (q, J = 6.6, 1H), 3.73 (dq, J = 9, 6.6, 
1H), 3.30 (m, 1H), 2.09-2.01 (m, 2H), 1.89-1.79 (m, 2H), 1.33 (d, J = 6.6 Hz, 3H), 1.19 (d, J = 
6.6 Hz, 3H), 1.20 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 196.4, 176.6, 142.7, 127.2, 94.7, 90.4, 
80.2, 70.2, 69.8, 38.9, 28.2, 26.9, 25.8, 17.9, 15.0; CIHRMS: Calculated for 
[C17H26NaO6+]:349.3745.  Found: 349.3750. 
 
100 
 
((2R,5S,6R)-4-((2’S,6’R)-5,6-dihydro-5-(4-acetate)-6-methyl-2H-pyran-2-yloxy)-3,4,5,6-
tetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl pivalate (39). 
OO
O
O
OAc
O
 
A solution of pyranone 38 (50 mg, 2.74 mmol) in CH2Cl2 (1.5 mL) and 0.4 M CeCl3/MeOH (1.5 
mL) was cooled to -78 °C. NaBH4 (58.4 mg, 1.54 mmol) was added and the reaction mixture 
was stirred for 4 h at -78 °C. The resulting solution was diluted with ether (10 mL), quenched 
with 5 mL of saturated NaHCO3, extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and 
concentrated under reduced pressure. The crude product was dissolved in CH2Cl2 (1.5 mL) and 
DMAP (10 mg) and acetic anhydride (2 mL) was added.  After 10 min the reaction was 
quenched by adding of Et2O (5 mL) and 10 mL of satd. aq. NaHCO3. Resulting mixture was 
extracted (3 x 10 mL) with Et2O, dried over Na2SO4 and concentrated under reduced pressure. 
The crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/hexanes to give allylic acetate 39 (65 mg, 0.65 mmol, 70%) as a yellow oil: Rf (30% 
EtOAc/hexanes) = 0.5; [α]21  D  = -65 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 2933, 1731, 1725, 
1443, 1368, 1246, 1166, 1114, 1066, 1011, 940, 818; 1H NMR; 1H NMR (600 MHz, CDCl3) δ 
6.02 (s, 1H), 5.85 (d, J = 10.2, 1H), 5.77 (ddd, J = 10.2, 2.4, 2.4 1H), 5.05 (m, 1H), 5.03 (m, 1H), 
3.99 (dq, J = 9.6, 6.6, 1H), 3.76 (dq, J = 9.6, 6.6, 1H), 3.30 (m, 1H), 2.06 (s, 3H), 1.89-1.79 (m, 
2H), 1.20 (d, J = 6.6 Hz, 3H), , 1.21 (s, 9H) 1.19 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, 
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CDCl3) δ 177.1, 170.7, 130.2, 127.6, 96.3, 91.0, 80.1, 71.0, 70.5, 65.0, 39.3, 28.7, 27.3, 26.6, 
21.2, 18.3, 18.1; CIHRMS: Calculated for [C19H30NaO7+]:393.4271.  Found: 393.4269. 
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2-Bromo-8-hydroxy-1,4-dimethoxynaphthalene 33‡‡ 
OMe
OMe
Br
Br
O LDA
+
OMe
OMe
Br
O
OMe
OMe
Br
OH
H3O+
 
To a solution of LDA in THF at -78 °C was added furan (), and 2,5-dibromo-1,4-
dimethoxybenzene 31 was slowly added.  The solution was stirred at -78 °C for 30 min, 
quenched by the addition of 10 mL of satd. aq. NaHCO3, extracted (3 x 10 mL) with Et2O, dried 
over Na2SO4 and concentrated under reduced pressure.  
1H NMR (600 MHz, CDCl3) δ 7.06 (dd, J = 6, 1.8 Hz, 1H), 7.01 (dd, J = 6, 1.8 Hz, 1H), 6.78 (s, 
1H), 5.97 (dd, J = 6, 1.8 Hz, 1H), 5.87 (dd, J = 1, 1 Hz, 1H), 3.84 (S, 3H), 3.76 (s, 3H). 
The crude cyclo-adduct 32 was dissolved in MeOH/H2O at RT and then HCl (6M) was added.  
After the reaction was refluxed for 8 hr, it was cooled to room temperature. The reaction was 
quenched with 10 mL of satd. aq. NaHCO3, extracted (3 x 10 mL) with Et2O, dried over Na2SO4 
and concentrated under reduced pressure.  The crude product was purified by flash 
chromatography using hexane–ethyl acetate (4:1) as eluent to afford 12 (356 mg, 94%) as a tan 
solid. 
                                                
‡‡ G. M. L. Cragg, R. G. F. Giles and G. H. P. Roos J. Chem. Soc., Perkin Trans. 1, 1975, 1339 – 1342. 
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1H NMR (600 MHz, CDCl3) δ 9.37 (S, 1H), 7.68 (dd, J = 8.4, 0.6 Hz, 1H), 7.40 (dd, J = 8.1, 8.1 
Hz, 1H), 6.94 (dd, J = 7.8, 0.6 Hz, 1H), 6.82 (s, 1H), 4.00 (s, 3H), 3.94 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ 153.2, 153.0, 146.3, 127.7, 127.7, 118.3, 113.9, 112.6, 110.7, 108.4, 62.8, 56.2. 
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(2R,3S,4R,6R)-6-(7-bromo-5,8-dimethoxynaphthalenyloxy)-2-methyl-3-((2S,5S,6S)-6-
methyl-5-((2R,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-
yloxy)-tetrahydro-2H-pyran-4-yl acetate (44 ): 
(2R,3S,4R,6S)-6-(7-bromo-5,8-dimethoxynaphthalenyloxy)-2-methyl-3-((2S,5S,6S)-6-
methyl-5-((2R,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-
yloxy)-tetrahydro-2H-pyran-4-yl acetate (44β): 
OMe
OMe
Br
O O
O
O
O
O
O
OO
 
To a THF (0.5 mL) solution of alcohol 43 (50 mg, 0.121 mmol), phenol 33 (68 mg, 0.242 mmol) 
and PPh3 (54.7 mg, 0.242 mmol) was added DIAD (48 µL) at room temperature. The reaction 
mixture was stirred at room temperature for 48 h. Reaction mixture was washed with 2 mL of 
satd. aq. NaHCO3, extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4 and concentrated under 
reduced pressure.  The crude product was purified using silica gel flash chromatography eluting 
with 20% EtOAc/hexanes to give 40 (67 mg, 0.13 mmol, 82%) as a mixture of diastereomers: Rf 
(30% EtOAc/hexanes) = 0.20; [α]21  D  = -26.8 (c = 1.0, CH2Cl2); 
As an inseparable mixture of stereo-isomers: 
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IR (thin film, cm-1) 2934, 1737, 1701, 1579, 1508, 1335, 1238;  
Major α-isomer:  1H NMR (600 MHz, CDCl3) δ 7.94 (dd, J = 8.4, 1.2 Hz, 1H), 7.40 (dd, J = 
8.1, 8.1 Hz, 1H), 7.25 (m, 1H), 6.94 (m, 1H), 6.87 (dd, J = 10.2, 3.6 Hz, 1H), 6.10 (d, J = 10.2 
Hz, 1H), 5.56 (d, J = 3.0 Hz, 1H), 5.23 (d, J = 3.6 Hz, 1H), 5.00 (d, J = 0.5 Hz, 1H), 4.56 (d, J = 
6.6, 1H), 4.11 (q, J = 6.6, 1H), 4.06 (m, 1H), 3.963 (s, 3H), 3.96 (s, 3H), 3.73-3.58 (m 2H), 3.52-
3.45 (m 2H), 2.70 (dd, J = 13.2, 5.4, Hz, 1H), 2.2-1.80 (m, 2H), 2.10 (s, 3H), 1.4-1.19 (m, 2H), 
1.32 (d, J = 6.6, 3H), 1.26 (d, J = 6.6, 3H), 1.21 (d, J = 6.6, 3H);  
13C NMR for the Major α-isomer could not be determined:  
CIHRMS Calcd for [C32H39BrNaO11]+: 701.1573, Found 701.1570. 
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D: Experimental Procedures for Chapter III: 
Methyl 4-(benzyloxy)-2-hydroxybenzoate (61)§§ 
BnO OH
OMe
O  
 
Methyl 2,4-dihydroxy-benzoate 60 (20.0 g, 119 mmol) was dissolved in 240 ml of acetone, 
followed by adding tetrabutylammonium iodide (0.132 g, 0.357 mmol), potassium carbonate 
(16.4 g, 119 mmol) and benzyl bromide (22.4 g, 131 mol). Resulting solution was heated up to 
reflux for 5 hours. After cooling off to room temperature, the reaction solution was filtered and 
concentrated under reduced pressure to give a light yellow solid, which was dissolved again in 
ethyl acetate. This ethyl acetate solution was washed with water (3 x 200 ml) and brine (200 ml), 
and concentrated to give white solid. The resulting solid was purified by recrystallization from 
methanol to give a white solid 61 (26.3 g, 102 mmol). Yield: 86%. mp  103–105 °C. 1H NMR 
(270 MHz, CDCl3): δ 11.0 (s, 1H), 7.74 (d, J = 9.4 Hz, 1H), 7.37–7.40 (m, 5H), 6.48–6.53 (m, 
2H), 5.07 (s, 2H), 3.90 (s, 3H). 
 
 
                                                
§§ This procedure provided material with melting point and 1HNMR that matched that reported in the literature, see: 
K. Tangdenpaisal, S. Sualek, S. Ruchirawat and P. Ploypradith Tetrahedron 2009, 65, 4316-4325. 
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Methyl 4-(benzoloxy)-2-(trifluromethylsulfonyloxy)benzoate (62) 
BnO OTf
OMe
O  
To a solution of 8.31 g (32.2 mmol) of methyl 4-(benzyloxy)-2-hydroxybenzoate 61 and 16.55 
ml of pyridine (16.6 mmol) at -10 °C was added dropwise 10.0 g (35.4 mmol) of 
trifluoromethanesulfonic anhydride. After 10 min of stirring at -10 °C followed by an additional 
2 h of stirring at room temperature, the reaction mixture was heated up to 40 °C for 24 hours. 
The reaction mixture was then poured into a mixture of 200 ml water and 200 ml ether. The 
organic layer was separated, washed with water (200 ml x 2), 10% HCl solution (200 ml x 2) and 
brine (200 ml), dried over anhydrous sodium sulfate and concentrated under reduced pressure. 
The residue was purified by flash chromatography (5% ether in hexane) to give 62 as a white 
solid (11.91 g, 30.3 mmol, 95%): mp 56-57 °C; IR 1729, 1616, 1426, 1134, 862; 1H NMR (600 
MHz, CDCl3) δ 8.06 (d, J = 9.0 Hz, 1H), 7.39 (m, 5H), 7.03 (dd, J = 9.0, 1.8 Hz, 1H), 6.87 (d, J 
= 1.8 Hz, 1H), 5.13 (s, 2H), 3.93 (s, 3H); 13C NMR (150 MHz, CDCl3) 163.9, 163.0, 149.5, 
135.1, 134.1, 128.8, 128.6, 127.5, 119.8, 116.5, 114.2, 109.7, 70.9, 52.3; HRCIMS Calcd for 
[C11H16O5H+]: 391.0458, Found 391.0455. 
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Methyl 4-(benzyloxy)-2-(prop-1-ynyl)benzoate (63) 
BnO
OMe
O  
A mixture of triflate 62 (13.8 g, 35.4 mmol), Pd(PPh3)2Cl2 (2.48 g, 3.54 mmol) and CuI (1.35 g, 
7.08 mmol) was combined in a flask topped with dry ice trap and was vacuumed for 10 min, 18.5 
ml of N,N-diisopropylethylamine (106.3 mmol) was added via a syringe followed by adding 110 
ml DMF. The dry-ice trap was filled with dry ice to cool down the system, and large excess of 
gaseous propyne was added using balloons. After 24 hours at room temperature, the DMF was 
removed by vacuum. The residue was purified by flash chromatography (5% ether in hexane) to 
give product 63 (8.95 g, 32 mmol, 90%) as a white solid: mp 75-77 °C; IR 2944, 1718, 1591, 
1248, 752; 1H NMR (600 MHz, CDCl3) 7.89 (d, J = 9.0 Hz, 1H), 7.37 (m, 5H), 7.10 (d, J = 3.0 
Hz, 1H), 6.90 (dd, J = 9.0, 3.0 Hz, 1H), 5.09 (s, 2H), 3.88 (s, 3H), 2.13 (s, 3H); 13C NMR (150 
MHz, CDCl3) 166.3, 161.1, 136.1, 132.4, 128.7, 128.2, 127.5, 126.7, 124.2, 119.7, 114.4, 91.6, 
78.5, 70.1, 51.8, 4.8; CIHRMS Calcd for [C18H16O3H]+:  281.1172.  Found 281.1171. 
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4-(benzyloxy)-2-(prop-1-ynyl) benzoic acid (64) 
BnO
OH
O  
 
Ester 63 (3.03 g, 10.82 mmol) was dissolved in 325 ml of methanol at room temperature, stirred 
until the solution was clear. 108 ml water was added followed by the addition of LiOH 
monohydrate (4.54 g, 108.2 mmol). Track the reaction by TLC. After 14 hours, the reaction was 
diluted with ammonium chloride until the pH reached ~8, followed by adding 10% HCl solution 
until the pH reached ~4. Leave the flask in iced bath for about 20 minutes. Collect the white 
solid appeared during acidification by filtration. The solid was purified by flash chromatography 
(50% ethyl acetate in hexane) to give product 64 (2.06 g, 7.74 mmol, 72%) as a white solid: mp 
175-176 °C; IR 3840, 2971, 1686, 1367, 1217; 1H NMR (600 MHz, CDCl3) 8.06 (d, J = 9.0 Hz, 
1H), 7.39 (m, 5H), 7.13 (d, J = 2.4 Hz, 1H), 6.90 (dd, J = 9.0, 2.4 Hz, 1H), 5.12 (s, 2H), 2.16 (s, 
3H); 13C NMR (150 MHz, CDCl3) 168.0, 161.8, 135.9, 133.7, 128.7, 128.3, 127.5, 126.1, 123.0, 
119.7, 114.9, 93.7, 78.1, 70.2, 4.8; CIHRMS Calcd for [C17H14O3H]+:  267.1016.  Found 
267.1015. 
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(4-benzyloxy)-2-(prop-1-ynyl)benzoylazide (67) 
BnO
N3
O  
 
The solution of carboxylic acid 64 (200 mg, 0.75 mmol) in 2 ml benzene was cooled down to 0 
°C, triethylamine (0.11 mL, 0.79 mmol) and DPPA 66 (0.163 mL, 0.752 mmol) were added. 
After 2 hours of stirring at room temperature, the reaction mixture was poured into 10 ml cold 
water, extracted with ether (3 x 20 ml). The organic layers were combined, dried over sodium 
sulfate anhydrous and concentrated. The resulting light yellow solid 67 was dried under a 
vacuum for 1-2 hours and used in the next step without further purification. mp 104-106 °C; IR 
2921, 2142, 1683, 1523, 1292, 1186, 877; 1H NMR (600 MHz, CDCl3) 8.05 (d, J = 9.0 Hz, 1H), 
7.34 (m, 5H), 6.96 (d, J = 3.0 Hz, 1H), 6.92 (dd, J = 9.0, 3.0 Hz, 1H), 5.00 (s, 2H), 2.11 (s, 3H); 
13C NMR (150 MHz, CDCl3) 154.6, 153.5, 136.6, 131.7, 128.6, 128.0, 127.4, 119.8, 117.5, 
115.9, 114.2, 93.6, 74.5, 70.3, 4.5; CIHRMS Calcd for [C17H13N3O2H]+:  292.1081.  Found 
292.1082. 
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4-(benzyloxy-1-isocyanato-2-ynyl) benzene (68) 
BnO
N
C
O
 
 
A solution of compound 67 (146 mg, 0.5 mmol) in 4 ml toluene was heated up to 95 °C for 
around 4 hours (TLC was used to track the reaction). The toluene was removed by vacuum. The 
residue was dissolved in ether with the remaining solid being filter off. The solution was 
concentrated to give 68 as a light yellow solid (132 mg, 0.5 mmol). The crude isocyanate was 
used without further purification.  mp 104-106 °C; IR 2280, 1193, 834, 758, 698; 1H NMR (600 
MHz, CDCl3) 7.35 (m, 5H), 6.96 (d, J = 3.0 Hz, 1H), 6.89 (d, J = 9.0 Hz, 1H), 6.80 (dd, J = 9.0, 
3.0 Hz, 1H), 5.00 (s, 2H), 2.10 (s, 3H); 13C NMR (150 MHz, CDCl3) 156.0, 136.5, 128.6, 128.5, 
128.1, 127.4, 127.3, 124.2, 122.2, 117.5, 115.8, 95.2, 75.7, 70.4, 4.4; CIHRMS Calcd for 
[C17H13NO2H]+:  264.1019.  Found 292.1019. 
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9-(benzyloxy)-11-methyl-6H-indolo(2,3-b)(1,6)naphthyridine (71) 
BnO
N
H
N
N
CH3
 
 
Isocyanate 68 (130 mg, 0.49 mmol) was dissolved in 20 ml of dry p-xylene, followed by addition 
of iminophosphorane 69 (192 mg, 0.54 mmol). Resulting solution was heated up under reflux for 
15 hours after was stirred at room temperature under argon protection for 2 hours. Para-xylene 
was removed by vacuum, after three cycles of washing the concentrated residue with diethyl 
ether, centrifugation, and decanting the supernatant liquid, the residual solid was heated under 
reflux in 100 ml of benzene for 1 hour. The mixture was allowed to cool to room temperature 
followed by centrifugation and decanting the supernatant liquid. The remaining solid was 
pumped to dryness in vacuo to afford 71 (40 mg, 0.12 mmol, 24%) as a yellow solid: compound 
turned black without melting at 311 °C; IR 2645, 1602, 1480, 1219, 820; 1H NMR (600 MHz, 
DMSO) 11.83 (s, 1H), 9.68 (s, 1H), 8.61 (d, J = 6.0 Hz, 1H), 7.94 (d, J = 9.0 Hz, 1H), 7.76 (d, J 
= 6.0 Hz , 1H), 7.54 (d, J = 9.0 Hz , 1H), 7.43 (m, 5H), 7.30 (dd, J = 9.0, 3.0 Hz, 1H), 5.26 (s, 
2H), 3.25 (s, 3H); 13C NMR (150 MHz, DMSO) 155.2, 153.4, 150.2, 149.3, 145.8, 141.0, 137.9, 
136.3, 128.9, 128.3, 128.2, 121.9, 120.7, 119.8, 117.7, 117.2, 112.2, 110.1, 70.8, 14.7; CIHRMS 
Calcd for [C22H17N3OH]+:  340.1444.  Found 340.1443. 
 
113 
 
Methyl 4-(benzyloxy)-2-(3-hydroxyprop-1-ynyl)benzoate (75) 
BnO
OMe
O
OH
 
To a solution of triflate 62 (195 mg, 0.5 mmol), diethylamine (1.03 ml, 10 mmol) and tetra-n-
butylammonium iodide (554 mg, 1.5 mmol) in DMF (1 ml) were added 
dichlorobis(triphenylphosphine) palladium (14 mg, 0.02 mmol) and copper iodide (11.4 mg, 0.06 
mmol). The reaction mixture was stirred for 5 min at room temperature, and propargyl alcohol 
(0.058 ml, 1 mmol) was added at same temperature. Temperature was raised to 70 °C, and the 
reaction was stirred for 4 hours. After the mixture was cooled down to room temperature, 20 ml 
saturated ammonium chloride was added to reaction mixture, and extracted with ether (3 x 50 
ml). Organic layers were combined, washed with brine (100 ml), dried over anhydrous sodium 
sulfate and concentrated under reduced pressure. The residue was purified by flash 
chromatography (20% ether in hexane) to give 75 as a white solid (117 mg, 0.40 mmol, 79%): 
mp 90-91 °C; IR 1708, 1594, 1198, 1006, 784; 1H NMR (600 MHz, CDCl3) 7.90 (d, J = 9.0 Hz, 
1H), 7.36 (m, 5H), 7.10 (d, J = 3.0 Hz, 1H), 6.91 (dd, J = 9.0, 3.0 Hz, 1H), 5.06 (s, 2H), 4.53 (s, 
2H), 3.96 (s, 3H); 2.26 (s, 1H) 13C NMR (150 MHz, CDCl3) 166.0, 161.2, 135.8, 132.4, 128.6, 
128.2, 127.4, 125.4, 123.9, 119.5, 115.0, 93.0, 84.0, 70.1, 51.9, 51.5; CIHRMS Calcd for 
[C18H16O4H]+:  297.1121.  Found 297.1122. 
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Methyl 4-(benzyloxy)-2-(3-(tert-butyldimethylsilyloxy)prop-1-ynyl)benzoate (74) 
BnO
OMe
O
OTBS
 
To a solution of triflate 62 (195 mg, 0.5 mmol), diethylamine (1.03 ml, 10 mmol) and tetra-n-
butylammonium iodide (554 mg, 1.5 mmol) in DMF (1 ml) were added 
dichlorobis(triphenylphosine) palladium (14 mg, 0.02 mmol) and copper iodide (11.4 mg, 0.06 
mmol). The reaction mixture was stirred for 5 min at room temperature, and TBS protected 
propargyl alcohol (0.20 ml, 1 mmol) was added at same temperature. After being stirred at 70°C 
for 4 hours, the mixture was cooled down to room temperature, and 20 ml saturated ammonium 
chloride was added to reaction mixture, extracted with ether (3x50 ml). Organic layers were 
combined, washed with brine (100 ml), dried over anhydrous sodium sulfate and concentrated 
under reduced pressure. The residue was purified by flash chromatography (20% ether in hexane) 
to give 74 as a light yellow liquid (165 mg, 0.40 mmol, 81%): IR 2953, 2252, 1721, 1597, 1251, 
905, 695; 1H NMR (600 MHz, CDCl3) 7.89 (d, J = 9.0 Hz, 1H), 7.36 (m, 5H), 7.11 (d, J = 3.0 Hz, 
1H), 6.91 (dd, J = 9.0, 3.0 Hz, 1H), 5.07 (s, 2H), 4.60 (s, 2H), 3.86 (s, 3H), 0.93 (s, 9H), 0.16 (s, 
6H); 13C NMR (150 MHz, CDCl3) 166.0, 161.0, 135.9, 132.4, 128.6, 128.2, 127.4, 125.4, 124.3, 
119.7, 114.9, 93.0, 83.3, 70.1, 52.4, 51.8, 25.8, 18.3, -5.14; CIHRMS Calcd for [C24H30O4SiH]+:  
411.1986.  Found 411.1989. 
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Methyl 4-(benzyloxy)-2-(3-(triisopropylsilyloxy)prop-1-ynyl)benzoate (76) 
BnO
OMe
O
OTIPS
 
Compound 75 (148 mg, 0.5 mmol) was dissolved in 1 ml methylene chloride, TIPS chloride (116 
mg, 0.6 mmol), triethylamine (0.14 ml, 1 mmol) and DMAP (6 mg, 0.05 mmol) were added. The 
reaction mixture was poured into 10 ml of water after stirring overnight at room temperature, and 
was extracted by ether (3x50 ml). The residue was purified by flash chromatography (10% ether 
in hexane) to give 76 as a light yellow liquid (226 mg, 0.50 mmol, 100%): IR 2924, 1694, 1593, 
1365, 1216, 882; 1H NMR (600 MHz, CDCl3) 7.89 (d, J = 9.0 Hz, 1H), 7.36 (m, 5H), 7.11 (d, J 
= 3.0 Hz, 1H), 6.91 (dd, J = 9.0, 3.0 Hz, 1H), 5.07 (s, 2H), 4.66 (s, 2H), 3.86 (s, 3H), 1.10 (s, 
18H), 1.09 (s, 3H); 13C NMR (150 MHz, CDCl3) 166.1, 161.1, 136.0, 132.4, 128.7, 128.2, 127.5, 
125.5, 124.3, 119.7, 114.9, 93.2, 83.1, 70.2, 52.7, 51.8, 17.9, 12.0; CIHRMS Calcd for 
[C27H36O4SiH]+:  453.2456.  Found 453.2460. 
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4-(benzyloxy)-2-(3-(triisopropylsilyloxy)prop-1-ynyl)benzoic acid (77) 
BnO
OH
O
OTIPS
 
Compound 76 (928 mg, 2.05 mmol) was dissolved in 60 ml methanol/20 ml water, and lithium 
hydroxide monohydrate (1.29 g, 30.8 mmol) was added after all solid dissoved. The resulting 
reaction mixture was stirred at room temperature for 15 hours. The solvent was removed by 
reduced pressure, the solid left behind was dissolved in 100 ml of water, 10% HCl solution was 
used to adjust PH to about 3. Extracted the water solution with ether (3x200 ml), ether was 
combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The 
solid was purified by flash chromatography (20 % ether in hexane) to give 77 as a white solid 
(264 mg, 0.60 mmol, 55% based on reacted starting material): m.p. 112-114 °C; IR 2944, 1727, 
1597, 1328, 1283, 1190, 1068, 882; 1H NMR (600 MHz, CDCl3) 8.02 (d, J = 9.0 Hz, 1H), 7.36 
(m, 5H), 7.13 (d, J = 3.0 Hz, 1H), 6.95 (dd, J = 9.0, 3.0 Hz, 1H), 5.10 (s, 2H), 4.66 (s, 2H), 1.10 
(s, 18H), 1.09 (s, 3H); 13C NMR (150 MHz, CDCl3) 169.8, 161.7. 135.9, 133.5, 128.7, 128.3, 
127.5, 125.9, 123.2, 119.9, 115.1, 94.4, 82.8, 70.3, 52.7, 17.9, 12.1; CIHRMS Calcd for 
[C26H34O4SiH]+:  439.2299.  Found 453.2302. 
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 Camptothecin Acetate (90):*** 
N
N
O
O
OO
O  
CPT (500 mg) and LiBr (500 mg) was dissolved in Ac2O (5 mL), then the resulting mixture was 
stirred for 48 h at 80 °C. After cooling to room temperature, 30 mL of hexane was added to the 
reaction mixture while stirring. The product precipitated from hexane was collected by filtration 
and washed with 45 mL of hexane (15 mL × 3). After drying under air for 1 h, a gray-white 
powder 90 (515 mg, 92%) was obtained. mp 273 °C; IR (thin film, cm-1) 3011, 1748, 1668, 1657, 
1618, 1229, 1047, 751, 744, 723; 1H NMR (CDCl3, 600 MHz) δ 8.42 (s, 1H), 8.26 (d, J = 8.4 Hz, 
1H), 7.95 (d, J = 8.4 Hz, 1H), 7.85 (dd, J = 7.2 Hz, 1H), 7.69 (dd, J = 7.2 Hz, 1H), 7.29 (s, 1H), 
5.67 (d, J = 17.4 Hz, 1H), 5.41 (d, J = 17.4 Hz, 1H), 5.29 (d, J = 17.4 Hz, 2H), 2.29 (m, 1H), 
2.23 (s, 3H), 2.15 (m, 1H), 0.98 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 150 MHz) δ 170.1, 167.7, 
157.6, 152.5, 148.9, 146.2, 146.1, 131.6, 131.0, 129.7, 128.7, 128.5, 128.3, 120.7, 96.4, 76.1, 
67.3, 50.1, 32.1, 21.0, 7.8. CIHRMS: Calculated for [C22H18N2O5Na+]: 413.1113.  Found: 
413.1109. 
                                                
*** This procedure provided material with melting point, IR, 1H NMR, and 13C NMR that matched that reported in 
the literature, see: N. Ravindranath, C. Ramesh, M. R. Reddy, K. V. N. S. Srinivas, and B. Das Syn. Commun. 2003, 
33, 4029–4035. 
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Camptothecin Acetate N-oxide (91): 
N
N
O
O
OO
O
O
 
A solution of compound 90 (500 mg) in EtOAc (15 mL) and CH2Cl2 (15 mL) was added excess 
75% mCPBA (2 g), and the reaction mixture was stirred at 80 °C for 24 h. After cooling to room 
temperature, the reaction was washed with 1N NaOH (2 x 15 mL), then saturated NaHCO3 (15 
mL). The organic layer was washed with H2O and brine, dried with Na2SO4 and evaporated to 
dryness.  The crude oxide product 91 (540 mg) was used without further purification. mp 239 °C; 
IR (thin film, cm-1) 3563, 3022, 1748, 1660, 1619, 1609, 1231, 1049, 749; 1H NMR (CDCl3, 600 
MHz) δ 8.76 (d, J = 8.4 Hz, 1H), 7.99 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.85 (dd, J 
= 7.8 Hz, 1H), 7.74 (dd, J = 7.8 Hz, 1H), 5.63 (d, J = 17.4 Hz, 1H), 5.36 (d, J = 17.4 Hz, 1H), 
5.27 (d, J = 19.8 Hz, 2H), 2.26 (m, 1H), 2.19 (s, 3H), 2.14 (m, 1H), 0.96 (t, J = 7.2 Hz, 3H); 13C 
NMR (CDCl3, 150 MHz) δ 170.2, 167.6, 157.0, 146.2, 142.5, 141.0, 137.6, 131.2, 130.5, 130.3, 
130.0, 128.8, 121.5, 119.9, 119.3, 101.4, 75.9, 67.1, 50.6, 31.9, 20.8, 7.7; CIHRMS: Calculated 
for [C22H18N2O6Na+]: 429.1063.  Found: 429.1066. 
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7-Chloro Camptothecin Acetate (92): 
N
N
O
O
OO
O
Cl
 
The crude oxide product 91 (540 mg) in DMF (10 mL) was added oxalyl chloride (0.5 mL) 
dropwise. After the reaction mixture was stirred at room temperature for 2 h, saturated NaHCO3 
aqueous and CH2Cl2 were added. The organic layer was washed with H2O and brine, dried with 
Na2SO4 and concentrated under reduced pressure to give a residue, which was purified by 
column chromatography (silica; chloroform/acetone, 50:1~20:1) to afford the desired compound 
92 (410 mg, 76%) as a yellow solid. mp 267 °C; IR (thin film, cm-1) 3003, 1762, 1745, 1664, 
1618, 1231, 749; 1H NMR (CDCl3, 600 MHz) δ 8.31 (d, J = 8.4 Hz, 1H), 8.25 (d, J = 8.4 Hz, 
1H), 7.88 (dd, J = 7.8 Hz, 1H), 7.76 (dd, J = 7.8 Hz, 1H), 7.25 (s, 1H), 5.27 (d, J = 17.4 Hz, 2H), 
2.25 (m, 1H), 2.20 (s, 3H), 2.12(m, 1H), 0.96 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 150 MHz) δ 
169.9, 167.3, 157.1, 151.8, 149.4, 146.0, 145.6, 138.6, 131.5, 129.7, 129.0, 127.5, 126.2, 123.9, 
121.1, 96.9, 75.8, 67.0, 50.0, 31.7, 20.7, 7.5; HRMS (ESI) calcd. For [C22H17ClN2O5+Na]+: 
447.0724, Found: 447.0718. 
 
120 
 
7-(3-Tetrahydropyranyloxy)prop-1-ynyl Camptothecin Acetate (94): 
N
N
O
O
OO
O
OTHP
 
To a mixture of compound 92 (43 mg, 0.1 mmol), Pd(OAc)2 (0.01 mmol), rac-BINAP (0.02 
mmol) and potassium carbonate (56 mg, 0.4 mmol), under an argon atmosphere, was added a 
solution of tetrahydro-2-(2-propynloxy)-2H-pyran 93 (0.4 mmol) in degassed toluene (9 mL). 
After the reaction mixture was stirred at 100 °C for 6 h, the solvent was evaporated to give a 
residue, which was purified by flash column chromatography on silica gel (chloroform/acetone, 
50:1~20:1) to furnish compound 94 (40 mg, 75%) as a yellow oil solid. MP X; IR (thin film, cm-
1) 2947, 1751, 1668, 1615, 1230, 1020, 768. 1H NMR (CDCl3, 600 MHz) δ 8.34 (d, J = 7.8 Hz, 
1H), 8.21 (d, J = 7.8 Hz, 1H), 7.84 (dd, J = 7.8 Hz, 1H), 7.71 (dd, J = 7.8 Hz, 1H), 7.21 (s, 1H), 
5.67 (d, J = 16.8 Hz, 1H), 5.40 (d, J = 16.8 Hz, 1H), 5.30 (d, J = 19.2 Hz, 2H), 4.96 (t, J = 3.6 Hz, 
1H), 4.71 (d, J = 16.2 Hz, 2H), 3.95 (m, 1H), 3.63 (m, 1H), 2.27 (m, 1H), 2.21 (s, 3H), 2.15 (m, 
1H), 1.90-1.58 (m, 6H), 0.97 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 150 MHz) δ 170.1, 167.7, 
157.5, 151.8, 148.9, 146.3, 146.1, 131.2, 131.1, 130.1, 128.8, 127.9, 126.2, 125.5, 120.9, 101.4, 
97.9, 96.5, 78.6, 76.1, 67.3, 62.5, 55.0, 50.5, 32.0, 30.5, 25.5, 20.9, 19.2, 7.8; HRMS (ESI) calcd. 
For [C30H28N2O7+Na]+: 551.1794, Found: 551.1791. 
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7-(3-Hydroxy)prop-1-ynyl Camptothecin Acetate (98): 
N
N
O
O
OO
O
OH
 
To a solution of compound 94 (50 mg) in methanol (1 mL) and chloroform (1 ml) was added p-
toluenesulfonic acid (5 mg). The reaction mixture was stirred at room temperature for 1 h and 
evaporated to dryness. The residue was added saturated aq. NaHCO3, extracted with CH2Cl2, and 
purified by flash column chromatography on silica gel (chloroform/methanol, 80:1~50:1) to 
furnish compound 98 (40 mg, 95%) as a yellow solid. mp 280 °C; IR (thin film, cm-1) 3267 
(broad), 1744, 1658, 1228, 1049, 1019, 771, 723; 1H NMR (CDCl3, 600 MHz) δ 8.32 (d, J = 8.4 
Hz, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.85 (dd, J = 7.8 Hz, 1H), 7.71 (dd, J = 7.8 Hz, 1H), 7.27 (s, 
1H), 5.68 (d, J = 17.4 Hz, 1H), 5.41 (d, J = 17.4 Hz, 1H), 5.29 (d, J = 19.2 Hz, 2H), 4.75 (s, 2H), 
2.27 (m, 1H), 2.23 (s, 3H), 2.15 (m, 3H), 0.99 (t, J = 7.8 Hz, 3H); 13C NMR (CDCl3, 150 MHz) δ 
170.1, 167.7, 157.5, 151.6, 148.6, 146.3, 146.1, 131.4, 131.2, 129.9, 128.9, 127.8, 126.2, 121.0, 
97.0, 89.5, 78.4, 76.1, 67.2, 51.8, 50.6, 32.0, 20.9, 7.8; HRMS (ESI) calcd. For 
[C25H20N2NaO6+Na]+: 467.1219, Found: 467.1223. 
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O-t-butyldimetylsilyl SN38 (103): 
N
N
O
O
OHO
TBSO
 
A DMF (1 mL) solution of SN-38 (43 mg, 0.1 mmol) was cooled to 0 °C, and Et3N and TBSCl 
(50 mg) were added.  After stirring at 0 °C for 2 h, the reaction was quenched by adding 5 mL 
saturated aq. NaHCO3, extracted with CH2Cl2, dried (Na2SO4), and concentrated under reduced 
pressure. The crude product was purified using silica gel flash chromatography eluting with 
CH2Cl2/MeOH = 80:1~50:1 to give 44 mg (83%) of compound 103 as a white solid. mp  °C; IR 
(thin film, cm-1) 3003, 1762, 1745, 1664, 1618, 1231, 749; 1H NMR (CDCl3, 600 MHz) δ 8.11 (d, 
J = 8.4 Hz 1H), 7.65 (s, 1H), 7.38 (m, 2H), 5.64 (d, J = 16.2, 1H), 5.30 (d, J = 16.2, 1H), 5.23 (s, 
2H), 3.81 (s, 1H), 3.12 (q, J = 7.8 Hz, 2H), 1.92 (dq, J = 15.0, 7.8 Hz, 1H), 1.86 (dq, J = 15.0, 
7.8 Hz, 1H), 1.64 (s, 1H), 1.39 (t, J = 7.8 Hz, 3H), 1.05 (s, 9H), 1.03 (t, J = 7.2 Hz, 3H), 0.91 (s, 
9H), 0.31 (s, 6H); 13C NMR (CDCl3, 150 MHz) δ 174.1, 157.9, 155.4, 150.6, 150.1, 147.5, 145.7, 
143.9, 132.3, 128.4, 127.2, 126.2, 118.2, 110.7, 97.8, 76.1, 73.1, 49.6, 31.9, 25.8, 23.3, 18.6, 13.9, 
8.0, -4.0; HRMS (ESI) calcd. For [C28H34N2O5Si +H]+: 507.2315, Found: 507.2311. 
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O-t-butyldimetylsilyl SN38 Acetate (104): 
N
N
O
O
OO
O
TBSO
 
The TBS ether 103 (500 mg) and LiBr (500 mg) was dissolved in Ac2O (5 mL), and the resulting 
mixture was stirred for 48 h at 80 °C. After cooling to room temperature, 30 mL of hexane was 
added to the reaction mixture while stirring. The product precipitated from hexane was collected 
by filtration and washed with 45 mL of hexane (15 mL × 3). After drying under air for 1 h, a 
gray-white powder 104 (515 mg, 92%) was obtained. mp 212 °C; IR (thin film, cm-1) 3005, 1762, 
1755, 1750, 1664, 1618, 1231, 749; 1H NMR (CDCl3, 600 MHz) δ 8.09 (d, J = 8.4 Hz 1H), 7. 50 
(s, 1H), 7.48 (m, 2H), 5.67 (d, J = 16.2, 1H), 5.50 (d, J = 16.2, 1H), 5.30 (m, 2H), 3.21 (q, J = 7.8 
Hz, 2H), 2.37 (dq, J = 15.0, 7.8 Hz, 1H), 2.30 (s, 3H), 2.24 (dq, J = 15.0, 7.8 Hz, 1H), 1.49 (t, J = 
7.8 Hz, 3H), 1.15 (s, 9H), 1.08 (t, J = 7.2 Hz, 3H), 0.42(s, 6H); 13C NMR (CDCl3, 150 MHz) δ 
170.0, 167.9, 157.7, 155.4, 150.0, 147.3, 146.2, 145.6, 144.1, 132.0, 128.5, 127.1, 126.4, 119.7, 
110.8, 95.7, 76.1, 67.3, 49.5, 32.0, 25.9, 23.3, 20.9, 18.5, 13.9, 7.74, -4.1; HRMS (ESI) calcd. 
For [C30H36N2O6Si +H]+: 549.2421, Found: 549.2426. 
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SN38 acetate (102):††† 
N
N
O
O
OO
O
HO
 
A CH2Cl2 (5 mL) solution of compound 104 (550 mg) was cooled to 0 °C and a solution of 
HF•2Py. After cooling to room temperature, 30 mL of hexane was added to the reaction mixture 
while stirring. The product precipitated from hexane was collected by filtration and washed with 
45 mL of hexane (15 mL × 3). After drying under air for 1 h, a gray-white powder (515 mg, 92%) 
was obtained. Decomposes > 250 °C; IR (thin film, cm-1) 3350, 3005, 1762, 1755, 1750, 1664, 
1618, 1231, 749; 1H NMR (CDCl3/CD3OD, 600 MHz) δ 8.22 (d, J = 9.1 Hz, 1H), 7. 83 (d, J = 
2.7 Hz, 1H), 7.58 (dd, J = 9.1, 2.7 Hz, 1H), 7.18 (s, 1H), 5.68 (d, J = 17.0, 1H), 5.41 (d, J = 17.0, 
1H), 5.23 (m, 2H), 3.16 (q, J = 7.6 Hz, 2H), 2.32 (m, 2H), 2.20 (s, 3H), 1.38 (t, J = 7.8 Hz, 3H), 
0.99 (t, J = 7.2 Hz); HRMS (ESI) calcd. For [C24H22N2O6+H]+: 434.1478, Found: 434.1472. 
 
                                                
††† This sample was not soluble enough in any mixture of CDCl3/CD3OD to get a good 13C NMR data. 
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(4R,1’S,6’S)-4,11-diethyl-4-acetoxy-9-(6-methyl-5-oxo-6H-pyranyloxy)-1H-
Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (105): 
N
N
O
O
OAcO
O O
O
 
A CH2Cl2 (5 mL) solution of compound 102 (43 mg, 0.1 mmol) and compound 5(α-L) (35 mg, 
0.15 mmol) was cooled to 0 °C. A CH2Cl2 (1 mL) solution of Pd2(DBA)3•CHCl3 (3 mg, 2.5 
mol%) and PPh3 (4 mg, 10 mol%) was added to the reaction mixture at 0 °C. The reaction 
mixture was stirred at 0 oC for 2 h. The reaction mixture was quenched with 5 mL of saturated aq 
NaHCO3, extracted with CH2Cl2, dried (Na2SO4), and concentrated under reduced pressure. The 
crude product was purified using silica gel flash chromatography eluting with CHCl3/MeOH = 
80:1~50:1 to give 44 mg (83%) of compound 105. 
This product was unstable and only crude 1H NMR was obtained. 
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(4R,1’S,5’R,6’S)-4,11-diethyl-4-acetoxy-9-(6-methyl-5-hydroxy-6H-pyranyloxy)-1H-
Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (107) 
N
N
O
O
OO
O
O O
HO
 
Pyranone 105 (40 mg) was dissolved in 2 mL CH2Cl2, resulting solution was cooled to -78 °C, 2 
mL of 0.4 M CeCl3 in methanol solution was added in a dropwise fashion, followed by adding 
10 mg of NaBH4. By TLC tracking, the reaction was done after 1.5 h. The reaction mixture was 
diluted with 2 mL diethyl ether, quenched with 2 mL water, extracted with 3 x 20 mL diethyl 
ether, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography eluting with 80% EtOAc/Hexane.  At 
this stage only a crude 1H NMR was taken. 
Alternatively: 
A CH2Cl2 (5 mL) solution of compound 102 (43 mg, 0.1 mmol) and compound 106 (35 mg, 0.15 
mmol) was cooled to 0 °C. A CH2Cl2 (1 mL) solution of Pd2(DBA)3•CHCl3 (3 mg, 2.5 mol%) 
and PPh3 (4 mg, 10 mol%) was added to the reaction mixture at 0 °C. The reaction mixture was 
stirred at 0 oC for 2 h. The reaction mixture was quenched with 5 mL of saturated aq NaHCO3, 
extracted with CH2Cl2, dried (Na2SO4), and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography eluting with CHCl3/MeOH = 
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80:1~50:1 to give 44 mg (83%) of compound 107 as an oil. Rf (50% MeOH/EtOAc) = 0.20; 
[α]21  D = -50 (c = 0.1, CD3OD); IR (thin film, cm
-1) 3411, 3050, 2933, 1740, 1612, 1513, 1245, 
1161, 1032, 997, 819; 1H NMR (600 MHz, CD3OD) δ 8.05 (d, J = 9.0, 1H), 7.75 (d, J = 2.4 Hz, 
1H), 7,56 (dd, J = 9.0, 2.4 Hz, 1H), 7.30 (s, 1H), 5.67 (d, J = 1.2 Hz, 1H), 5.56 (d, J = 16.5 Hz, 
1H), 5.45 (d, J = 16.5 Hz, 1H), 5.21 (d, J = 18.0 Hz, 1H), 5.18 (d, J = 18.0 Hz, 1H), 4.12 (dd, J = 
3.0, 1.8 Hz, 1H), 3.92 (dd, J = 9.0, 3.6 Hz, 1H) 3.70 (dd, J = 4.2, 4.2 Hz, 1H), 3.65 (m, 1H), 3.51 
(m, 2H), 3.2-3.1 (m, 4H), 2.24 (s, 3H), 1.37 (dd, J = 7.8, 7.8 Hz, 3H), 1.24 (d, J = 6.6 Hz, 3H), 
1.04 (dd, J = 7.5, 7.5 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 171.6, 169.7, 159.1, 157.0, 151.3, 
148.6, 148.3, 146.7, 146.4, 132.3, 129,6, 129.4, 124.4, 120.2, 107.9, 100.3, 97.5, 77.7, 73.9, 72.4, 
72.1, 67.9, 66.6, 50.9, 30.8, 24.1, 20.7, 18.3, 14.1, 8.2; CIHRMS Calcd for [C30H32N2O10Na]+: 
603.1955, Found 603.1961. 
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(4R)-4,11-diethyl-4-acetoxy-9-oxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-
3,14(4H,12H)-dionyl-α-L-rhamno-pyranoside (108): 
N
N
O
O
OO
O
O O
HO OH
OH
 
 
To a t-butanol/acetone (4.3 ml, 1:1) solution of pyran 107 (20 mg, 4.3 mmol) at 0 °C was added 
a solution of (50% w/v) of N-methyl morpholine N-oxide / water (4.3 mL).  Crystalline OsO4 
(1.1 mg, 1 mol %) was added and the reaction was stirred for 12 h.  The reaction was quenched 
by adding EtOAc and satd. aq. NaHCO3. The organic layer was separated and concentrated. The 
crude product was purified using silica gel flash chromatography eluting with 50% 
EtOAc/hexanes to give triol 108 (21 mg, 85%) as a colorless oil. Rf (50% MeOH/EtOAc) = 0.20; 
[α]21  D = -50 (c = 0.1, CD3OD); IR (thin film, cm
-1) 3411, 3050, 2933, 1740, 1612, 1513, 1245, 
1161, 1032, 997, 819; 1H NMR (600 MHz, CD3OD) δ 8.05 (d, J = 9.0, 1H), 7.75 (d, J = 2.4 Hz, 
1H), 7,56 (dd, J = 9.0, 2.4 Hz, 1H), 7.30 (s, 1H), 5.67 (d, J = 1.2 Hz, 1H), 5.56 (d, J = 16.5 Hz, 
1H), 5.45 (d, J = 16.5 Hz, 1H), 5.21 (d, J = 18.0 Hz, 1H), 5.18 (d, J = 18.0 Hz, 1H), 4.12 (dd, J = 
3.0, 1.8 Hz, 1H), 3.92 (dd, J = 9.0, 3.6 Hz, 1H) 3.70 (dd, J = 4.2, 4.2 Hz, 1H), 3.65 (m, 1H), 3.51 
(m, 2H), 3.2-3.1 (m, 4H), 2.24 (s, 3H), 1.37 (dd, J = 7.8, 7.8 Hz, 3H), 1.24 (d, J = 6.6 Hz, 3H), 
1.04 (dd, J = 7.5, 7.5 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 171.6, 169.7, 159.1, 157.0, 151.3, 
148.6, 148.3, 146.7, 146.4, 132.3, 129,6, 129.4, 124.4, 120.2, 107.9, 100.3, 97.5, 77.7, 73.9, 72.4, 
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72.1, 67.9, 66.6, 50.9, 30.8, 24.1, 20.7, 18.3, 14.1, 8.2; CIHRMS Calcd for [C30H32N2O10Na]+: 
603.1955, Found 603.1961. 
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